

Review

Targeting Notch Trafficking and Processing in Cancers

Luca Pagliaro [†], Claudia Sorrentino [†] and Giovanni Roti ^{*}

Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy; luca.pagliaro@unipr.it (L.P.); claudia.sorrentino@unipr.it (C.S.)

^{*} Correspondence: giovanni.roti@unipr.it; Tel.: +39-0521-904062

[†] These authors contributed equally to this work.

Received: 6 July 2020; Accepted: 8 September 2020; Published: 29 September 2020



Abstract: The Notch family comprises a group of four ligand-dependent receptors that control evolutionarily conserved developmental and homeostatic processes and transmit signals to the microenvironment. NOTCH undergoes remodeling, maturation, and trafficking in a series of post-translational events, including glycosylation, ubiquitination, and endocytosis. The regulatory modifications occurring in the endoplasmic reticulum/Golgi precede the intramembrane γ -secretase proteolysis and the transfer of active NOTCH to the nucleus. Hence, NOTCH proteins coexist in different subcellular compartments and undergo continuous relocation. Various factors, including ion concentration, enzymatic activity, and co-regulatory elements control Notch trafficking. Interfering with these regulatory mechanisms represents an innovative therapeutic way to bar oncogenic Notch signaling. In this review, we briefly summarize the role of Notch signaling in cancer and describe the protein modifications required for NOTCH to relocate across different subcellular compartments. We focus on the functional relationship between these modifications and the corresponding therapeutic options, and our findings could support the development of trafficking modulators as a potential alternative to the well-known γ -secretase inhibitors.

Keywords: NOTCH1; SERCA; T-cell acute lymphoblastic leukemia; thapsigargin; trafficking; CAD204520

1. Introduction

In 1914, John S. Dexter described a heritable “perfect notched” phenotype in beaded *Drosophila* [1]. Thomas Hunt Morgan originally reported that mutant “beaded” wings appeared in 1910 from fly stocks that had been exposed to radium rays early in their lives [2,3]. In 1917, he showed that the “notch” phenotype was caused by a heterozygous deletion of a gene located on the X chromosome that was subsequently named “NOTCH” after the notched shape [4]. Only decades later, Spyros Artavanis-Tsakonas [5] and Michael Young [6] cloned the NOTCH receptor in the same experimental model and provided an initial description of the structure and functions of NOTCH [6]. Since then, the contribution of the Notch signaling has been described in many physiological processes, from embryogenesis to adult tissue commitment and homeostasis [7]. In the same way, NOTCH aberrancies have been reported in several diseases, including inherited syndromes [8] and numerous types of cancer [9].

2. The NOTCH Structure

In mammals, the “Notch family” comprises a group of four transmembrane receptor proteins (NOTCH1-4) that interact with ligands that are expressed in contacting cells. The ligands comprise three delta-like (Dll1, Dll3, and Dll4) and two jagged (Jag1 and Jag2) type I transmembrane proteins [10]. NOTCH receptors share a modular structure, which is assembled into functional

regions: an extracellular domain (N-ECD), an intracellular tail, and a connector between the two. Human NOTCH1 and NOTCH2 N-terminal domain N-ECD contains 36 homologous epidermal growth factor (EGF)-like tandem repeats and three Lin-12/Notch units (LNR), while that of NOTCH3 and NOTCH4 contains 34 and 29 repeats, respectively [11]. Adjacent to the LNR domain lies the juxtamembrane heterodimerization domain (HD), the linker between the N-ECD and NOTCH intracellular domain (N-ICD). N-ICD consists of a membrane proximal RBPJ-associated molecule (RAM) region, seven ankyrin-like repeats (ANK) [12,13], and a C-terminal transactivation domain (TAD) that harbors the nuclear localization sequences (NLS). The catalytic activity relies on presenilin (PSEN), which releases an N-ICD degradation domain containing the PEST sequence, a peptide sequence rich in proline, glutamate, serine, and threonine.

While the nuclear role of NOTCH has been thoroughly investigated [14], the cytoplasmic contribution of these proteins to physiological or tumor pathways is far from being completely understood. In this review, we focus on the mechanisms that control the Notch secretory pathway and the ways to exploit them for cancer therapeutics.

3. From Golgi to the Cell Membrane

The canonical Notch signaling pathway initiates in response to NOTCH ligands. The strength of receptor–ligand interactions and the fate of the nuclear signal are modulated by post-translational modifications occurring in the extracellular portion of NOTCH proteins [15] (Figure 1). The EGF-like repeats can be modified by the addition of an *O*-glucose or *O*-fucose transferred by the POGLUT1 (protein *O*-glucosyltransferase 1) [16–18] and POFUT1 (protein *O*-fucosyltransferase 1) [19,20], respectively. Interestingly, the combined addition of *O*-glucose or *O*-fucose stabilizes the EGF repeats in an additive manner and contributes to the cell surface expression of endogenous NOTCH1 in human embryonic kidney (HEK) 293T cells [21]. In mammalian NOTCH receptors, *O*-glucose glycans may be further modified by the addition of xylose residues at each of the EGF repeats [22]. Glucoside α 3-xylosyltransferases (GXylT1 and GXylT2) and xyloside α 3-xylosyltransferase (XXylT1), for example, extend the *O*-glucose monosaccharides added by POGLUT1 [23]. Recent data has demonstrated that 70% or more of the NOTCH1 and NOTCH2 *O*-glucose glycoforms on 12 out of 17 EGF repeats are xylose-extended [24]. In mechanistic studies, the authors demonstrated that xylosyl extension by GXylT1 and GXylT2 is not necessary for the trafficking of endogenous NOTCH1 and NOTCH2 in HEK293T cells, while it is required for a proper protein trafficking in cells overexpressing NOTCH1 and NOTCH2 [24].

The accumulation of *O*-fucose primes NOTCH receptors for the further formation of glycosylated NOTCH intermediates by members of the Fringe family (Radical (R), Manic (M), Lunatic (L)) in the trans-Golgi compartment. Fringe proteins add *N*-acetylglucosamine (GlcNAc) sugars to the *O*-fucose moiety. The pattern of fucose modifications modulates the relative response of NOTCH receptors to ligands of the Delta versus Jagged/Serrate classes. Fringe proteins, for example, potentiate interactions with Dll1 and reduce the responsiveness to Jag1 [25–27]. Takeuchi and colleagues also identified two novel *O*-glucosyltransferases, POGLUT2 and POGLUT3, which are responsible for the transfer of UDP-glucose on the 11th EGF repeat on serine 435, a distinct site from that of POGLUT1 [17]. Mutations occurring in Ser435 affect the NOTCH1 cell-surface presentation and, consequently, its activation upon interaction with Dll1 [28].




Figure 1. Schematic representation of Notch signaling and proteolytic processing. NOTCH receptors are cell surface receptor proteins. Interaction with mutual ligands activates two consecutive proteolytic cleavages at the extracellular site, one by a metalloprotease (ADAM10/TACE) (S2), followed by another by a γ -secretase (S3), resulting in the release of N-ICD. N-ICD is translocated into the nucleus where it interacts with a transcription-activating complex. In the presence of *NOTCH1* mutations, N-ICD is constitutively active, independent of ligand binding. the figure shows an overview of Notch trafficking routes and the corresponding targets for therapeutic intervention. N-FL: NOTCH full length; N-TM: NOTCH transmembrane; N-ICD: NOTCH intracellular domain.

During these maturation steps, full-length NOTCH (N-FL) proteins are subsequently cleaved within the so-called negative regulatory region (NRR) by a furin-like convertase at site “S1” in the trans-Golgi network. Proteolysis generates heteromeric single-pass transmembrane proteins of N-ECD that are non-covalently bound to the transmembrane NOTCH (N-TM) [29] and unstable in the presence of increasing concentrations of ethylenediaminetetraacetic acid (EDTA). EDTA mimics NOTCH activation [30], suggesting that disruption of Ca^{2+} homeostasis may alter the NOTCH processing [30]. As expected, furin knockout decreases NOTCH cleavage [31], as mutations occurring in the furin recognition sites [31]. It has also been suggested that furin processing cooperates with the Nodal pathway to enhance the post-translational maturation of NOTCH receptors. Nodal is a secretory protein that belongs to the transforming growth factor-beta (TGF- β) family and plays an essential role in vertebrate development [32]. Nodal binds type I and type II serine/threonine kinase

receptors using Cripto-1 as a co-receptor [33] to mediate the final translocation of SMAD4 (SMAD family member 4, Mothers against decapentaplegic homolog 4) into the nucleus and the transactivation of genes involved in proliferation and differentiation processes [33]. From a two-hybrid screen to isolate Cripto-1 binding partners, Watanabe and colleagues initially identified NOTCH3 among other potential targets. Confirmatory studies showed that all NOTCH isoforms bind to Cripto-1 and that in the human embryonic carcinoma cell line NTERA2/D1 cells, Cripto-1 knockdown significantly suppresses the induction of the Notch target genes hairy and enhancer of split (*HES-1*) and hairy and enhancer of split-related with YRPW motif (*HEY-1* and *-2*) after NOTCH ligand stimulation. In fact, N1-FL accumulates in Cripto-1-deficient cells, suggesting that the latter is required for proteolytic processing [34]. Collectively, these data suggest that these modifications are regulated at multiple levels: ion fluxes, enzymes, and co-regulators, providing several opportunities for therapeutic intervention (Figure 1).

4. From the Cell Membrane to the Nucleus

Once preprocessed in the ER/Golgi, NOTCH receptors migrate to the cell membrane and receive an activation (trans) or inhibitory (cis) signal [35] after ligand interaction. This binding induces a conformational change to clip off N-ECD [36–38]. This proteolytic cleavage (S2) is mediated by a zinc-dependent disintegrin and metalloprotease (ADAM10 or 17) and occurs within the NOTCH juxtamembrane extracellular domain, proximal to the N-TM, between residues Ala1710 and Val1711 of NOTCH1 [36,37]. Different roles of the metalloproteases have been reported. ADAM10 cleaves NOTCH upon a canonical activation, while ADAM17/TACE releases the N-TM of mutant peptides [39,40]. The short-lived S2 fragments are the substrate of the γ -secretase complex [41,42] (S3), a membrane-embedded protease complex comprising the enzyme PSEN1 or PSEN2 with presenilin enhancer-2 (PEN-2), anterior pharynx defective-1 (APH-1), and nicastrin (NCSTN) [43,44]. The active γ -secretase consists of APH-1 and PEN-2 directly linked to PSEN and NCSTN [45]. The catalytic activity relies on PSEN, which releases an N-ICD from, such as Gly1743 and Val1744 of N1-TM [41]. The RAM and ANK N-ICD motifs bind the DNA factor suppressor of hairless [Lag-1 or CSL (mammalian RBP)] and recruit the N-terminal helices of mastermind-like (MAML) family co-activator to generate a transcriptional complex (N-TC) [46]. In succession, MAML recruits the histone acetyl-transferases (p300/CBP) to transcribe, among other genes, *HES*, *HEY*, and *MYC* [47,48].

5. Endocytosis and Trafficking

Initial endocytosis studies focused on the role of ligand internalization. Loss-of-function mutations of *Shibire*, the *Drosophila* dynamin homolog [49], interfere with the ability of ligands to interact with NOTCH-presenting cells. However, endocytosis is not only reserved for ligands, but also for NOTCH receptors [50]. The trafficking of NOTCH receptors across cellular compartments is a limiting step in signal transmission. Briefly, NOTCH proteins travel through the ER/Golgi, from the cell surface to the nucleus and, eventually, follow degradation or recycling routes [51] (Figure 2). To do so, different E3-ubiquitin ligases, such as Deltex, Nedd4, and suppressor of Deltex/Itch (Su(Dx)/Itch for *Drosophila*/mammals), catalyze the monoubiquitination of NOTCH proteins [52] to trigger their internalization by early endosomes (EE) [51] in a clathrin-dependent manner [53,54]. NOTCH is subsequently sorted to other endocytic compartments, including recycling endosomes, multivesicular bodies (MVB)/late endosomes (LE), and lysosomes [51]. The removal of N-FL proteins is a key step at the EE level, wherein clathrin-endocytosed transmembrane proteins enter a GTPase Rab5 (Ras-related in brain)-positive compartment and are either directed towards the down-regulatory route or recycled back to the plasma membrane [51,55] by the action of Rab4 and Rab11 [55]. The selection between these two pathways may depend on covalent modifications or protein-binding partners. The non-activated NOTCH monoubiquitinated proteins are marked for degradation by the E3-ligases [56] that mature into intraluminal vesicles (IVs) and are degraded by an endosome-sorting complex required for transport (ESCRT). ESCRT consists of four (0–III) complexes that deliver ubiquitinated proteins

into multivesicular endosomes (MVEs) [57]. MVEs fuse with lysosomes containing hydrolytic enzymes [58]. the ubiquitination of NOTCH residues is unrestricted to N-FL proteins. the regulation of N-ICD stability depends on the phosphorylation of the PEST domain. Phospho-PEST recruits the SCF/Sel10/FBXW7 E3-ubiquitin ligase complex to control N-ICD ubiquitination, turnover, and degradation by the proteasome (Figure 1). FBXW7 is an E3-ubiquitin ligase that targets, among others, N-ICD, MYC, and cyclin E [59], to mediate protein degradation.




Figure 2. Overview of NOTCH endocytosis and vesicular trafficking. NOTCH proteins are monoubiquitinated by Deltex, Su(Dx)/Itch, Nedd4, and E3 ligase and endocytosed in clathrin-coated vesicles (CCV), resulting in Rab5-positive early endosomes (EEs). EEs might follow two different routes: (i) recycling back to the membrane through a Rab4/Rab11-positive endosome compartment and (ii) sorting into a Rab7-positive late endosome (LE), followed by ESCRT complex-mediated fusion into multivesicular endosome (MVE). the role of γ -secretase in EE and the release of N-ICD is less clear. From MVE, NOTCH proteins can be ectopically activated or MVE can fuse with the adaptors HOPS and AP-3 and, finally, with lysosomes, enabling NOTCH degradation. CCV: clathrin-coated vesicles; EE: early endosome; LE: late endosome; MVE: multi-vesicular endosome; N-FL: NOTCH full length; N-ICD: NOTCH intracellular domain.

However, the endosomal structures are not exclusively produced for trafficking. Recent evidence suggests that some proteolytic events, including γ -secretase cleavages, may equally occur in EE and LE [60], which partly explain the ligand-independent mechanism of NOTCH activation. the model of

ligand-independent receptor activation had been initially hypothesized in *Drosophila* [61], in which the loss of the E3-ubiquitin ligase Deltex led to a decrement of NOTCH internalization and, consequently, of its activation, suggesting that Deltex is implicated in the regulation of Notch endocytic trafficking. Deltex is an intracellular protein that binds to the cytoplasmic ankyrin repeats of NOTCH [62] and stabilizes it in the endocytic compartment to form a complex with adaptor proteins, such as AP-3 [63] and “homotypic fusion and vacuole protein sorting” (HOPS; [63]), that regulate NOTCH degradation. In fact, this complex shuffles NOTCH receptors to LE/MVB and is involved in endosomal trafficking toward the lysosome compartment, allowing the LE/lysosome fusion step [63,64] (Figure 2). During these steps in which the degradation drive is impaired, N-ICD is possibly released into the cytoplasm and, eventually, to the nucleus, through proteolytic cleavages in a ligand-independent way [65–67]. Secondary studies have confirmed that the loss of function of traffic-associated protein Lgd in *Drosophila* results in the ectopic activation of Notch signaling in a ligand-independent manner [68]. As previously mentioned, γ -secretase cleavage may occur in the endosomal compartment. Besides, some authors have shown a more efficient activity of γ -secretase in the endosomes due to their lower pH environment [60,69]; on the other hand, different observations have challenged this hypothesis by reporting the effective activity of γ -secretase in neutral pH conditions [70,71] and showing that, despite N-FL mutations that impair monoubiquitination, a less stable form of N-ICD can still be produced [72]. Hence, whether or not endosomal trafficking is necessary for N-ICD release is still not clear, being still under discussion. Furthermore, it may differ depending on the cell context.

6. Notch Signaling in Cancer

Notch regulates several cellular networks [73–76] and cross-talks whose pathways originate in close-contacting cells. It is not surprising that Notch signaling changes may contribute to oncogenesis, tumor maintenance, and escape [77,78]. Moreover, additional studies point to a role of Notch in immune surveillance [78,79] and in the tumor microenvironment (TME) [80–82]. Depending on the cell context, *NOTCH* may act as an oncogene or tumor suppressor but, more importantly, the degree of its contribution to the disease depends on the presence of activating or suppressing genetic aberrancies [77]. This heterogeneity explains why Notch downstream targets scarcely overlap across liquid and solid tumors. Only a few genes, such as *HES4*, *HEY1*, *MYC*, *NOTCH3*, *NRARP*, and *TFRC*, are similarly regulated in mutationally activated *NOTCH1*-driven cancers, such as T-cell acute lymphoblastic leukemia (T-ALL), mantle cell lymphoma (MCL), and breast cancer [83]. Through a collaborative effort, instead we showed that γ -secretase inhibitors (GSIs) regulate a similar set of genes in T-ALL and chronic lymphocytic leukemia (CLL), suggesting common mechanisms of transcriptional regulation in lymphoid malignancies [84].

6.1. *NOTCH* as an Oncogene

The transforming contribution of aberrant Notch signaling was initially described in T-ALL, an aggressive hematological malignancy that accounts for 15–20% of ALL cases [85]. In 1991, Ellisen and colleagues described a rare chromosome translocation, the t(7;9)(q34;q34.4), that juxtaposes the 3' region of N1-ICD to the 5' region of the *TCR β* gene. This translocation generates a *NOTCH1* fusion protein with ligand-independent activity [86]. Subsequent cancer modeling studies showed that aberrant N-ICD might lead to tumor formation or progression [87,88]. For example, exogenous expression of a *NOTCH1* plasmid lacking the N-ECD and N-TM domains in rat kidney cells led to the establishment of tumors in mice, compared to cells expressing wild-type *NOTCH1* proteins [87]. Similarly, transgenic mice overexpressing the *NOTCH1* homolog, *TAN1*, developed T-cell leukemia in 50% of the cases [88], supporting the notion that *NOTCH1* is a key oncogene in some cellular contexts.

Gain-of-function *NOTCH1* mutations are sequenced in 50–70% of T-ALL cases [89]. These mutations alter *NOTCH1* stability, causing differences in the extent of its ability to activate the downstream pathway [90]. the majority of aberrancies are class-1 mutations consisting of single amino acid substitutions, insertions, or deletions spanning the residues 1574–1622 on exons 26 and 27,

corresponding to the HD-N and HD-C-terminal domains [89]. These mutations destabilize NOTCH1 heterodimers in two ways. In class 1A mutants, N-TM and N-ECD separate spontaneously, exposing the S2 cleavage site on N-TM to the activity of ADAM metalloproteases [90]. In class 1B mutants, the HD domain exposure to the S2 site is slower and can occur spontaneously or in denaturing conditions [90]. In 2008, Sulis and colleagues reported a rare group of mutations that account for only 3% of T-ALLs; these mutations involve the juxtamembrane expansion domain (JME), which displaces the HD-LNR repeat complex away from the cell surface to increase ligand-independent or ligand-hypersensitive NOTCH1 activation [91]. Class 2 HD domain mutations include in-frame insertions of 14 residues in exon 27, adjacent to the S2 cleavage site. These mutations reduce the protective effect of the HD-LNR complex on the S2 site, exposing the site to the activity of metalloproteases [89,90]. The second hot spot for the *NOTCH* mutations occurs in the PEST domain, accounting for 15–20% of T-ALLs. As previously mentioned, the PEST domain contributes to the stability and degradation of N-ICD through the ubiquitin-proteasome pathway, acting as a major route of self-limitation of the Notch pathway. Frameshift or non-sense substitutions in exon 34 alter the ubiquitin ligase FBXW7 binding site, leading to increased levels of N1-ICD and subsequent constitutive Notch activation [89,92]. Similarly, mutations involving the arginine sites on FBXW7 may lead to prolonged N1-ICD signaling in the nucleus [93,94]. Mutations affecting the Notch degradation pathway are weaker than class 1 and 2 mutations [89,90,95]. However, in 25% of the mutant cases, HD and PEST mutations may co-occur, enhancing the oncogenic activation of this pathway [89]. While *NOTCH1* mutations represent disease-causing events in T-ALL, their role as biomarkers has been debated [96–99]. Most pieces of evidence indicate that event-free survival (EFS) has positive predictive value in both pediatric [96,97] and adult T-ALL [99].

Under physiological conditions, Notch activation is required to commit common lymphoid precursors toward T-cell differentiation at the expense of early B-cell development by inductive inhibition [100]. However, fine-tuned control of Notch signaling and the lack of it dictate B-cell maturation and differentiation [100]. For example, the expression and activation by Dll1 ligand of NOTCH2 are critical for splenic marginal B-cell development [101]. Consistently, *NOTCH2* haploinsufficiency results in a severe reduction of splenic marginal zone B cells in *Notch2^{+/f}*, CD19-Cre (*Notch2^{+/-}*) mice models [101], while gain-of-function *NOTCH2* mutations occur in 10–25% of splenic marginal zone lymphomas (SMZLs) [102,103]. It may be possible that the acquisition of *NOTCH* mutations in B-cell malignancies is a late event in carcinogenesis that occurs in mature B-cells, conferring them a more aggressive phenotype [104]. From 5% to 15% of clinical cases of CLL and MCL present a 2 bp frameshift deletion (P2514 or 2515fs) involving exon 34 on the PEST domain [105–108]. In contrast to PEST deletions observed in T-ALL, PEST mutations in CLL and MCL span a larger region [89,109] and are associated with a poor prognosis, compared to the outcome in wild-type patients. In a series of 309 newly diagnosed CLL cases, the presence of a *NOTCH1* mutation conferred a >3-fold increased risk of death and shorter overall survival (OS) ($p < 0.001$). These patients presented with aggressive clinical features, an increased risk of Richter's transformation, resistance to therapy, and a mutually exclusive correlation with *TP53* mutations [110]. Similarly, PEST mutations in diffuse large B-cell lymphoma (DLBCL) [107,111] are associated with a poor prognosis [112]. However, it has yet to be clarified how a single PEST mutation can activate Notch signaling. One hypothesis is that the interaction of malignant B-cells with the TME or with infiltrating macrophages leads to a cascade of events [113,114], culminating in the transactivation of Notch signaling. This may contribute to the development of mature B-cell malignancies, such as CLL and MCL [115,116]. Consistently, Dll4 triggers NOTCH1 expression in the PEST-deleted MCL cell line Mino, but not in the wild-type cell line Jeko-1 [117], and it rescues T-ALL or colorectal cancer cells from dormancy, thus activating NOTCH3 [118]. Collectively, these data suggest that, at least in some B-cell malignancies, *NOTCH* mutations cooperate with canonical signals and have obvious implications in cancer therapeutics.

The discovery of the oncogenic role of *NOTCH* in T-ALL anticipated the identification of *NOTCH* aberrations in solid tumors, such as lung adenocarcinoma [119], medulloblastoma [120], melanoma [121], colon cancer [122,123], and more frequently, in breast cancer [35,124]. Recent massive sequencing

efforts have demonstrated that chromosome translocations are responsible for generating N1-ICD or N2-ICD peptides in 10% of triple-negative breast cancers [125] and oncogenic mutations occurring in *NOTCH4* genes [126,127]. Additionally, the expression of NOTCH1 and Jag1 correlate with poor overall survival [128].

Ultimately, the activation of Notch signaling can follow a non-canonical pathway in response to a functional relationship with other signaling pathways, such as the Ras, Wnt, or hypoxia-dependent pathways [129–131]. While these effects are less clear, they might confirm that altered Notch signaling is among the most frequent aberrantly activated pathways in human cancers.

6.2. Notch as a Tumor Suppressor

While *NOTCH* acts as an oncogene in the majority of cancers, its tumor suppressor role is firmly established in other cancers. Loss-of-function *NOTCH* mutations are frequently detected in epithelial-derived tumor histotypes, such as skin squamous cell carcinoma (SCC) [132,133], head and neck [134,135], esophageal [136], and bladder carcinoma [137]. Here, frameshift or non-sense mutations are predominant and lead to the generation of truncated peptides that are unable to communicate with the cognate ligands [133–135]. In SCC, *NOTCH1* mutations exceed those in *NOTCH2* and *NOTCH3* [138,139]. Furthermore, in SCC *NOTCH1* conditional knockout murine models, epidermal and corneal hyperplasia preceded cutaneous skin carcinoma [140], suggesting that *NOTCH1* deletion causes an aberrant proliferation of cells at the basal epidermal layer [141,142]. It is not surprising that GSIs increase the risk of skin cancer, as noted in murine models [140,143,144] or clinical trials using semagacestat [145]. On the contrary, the activation of Notch signaling in the skin, along with the Wnt and Sonic-hedgehog pathways [140], control differentiation and cell-cycle arrest through cross-talk with p21, interferon regulatory factor (IRF6), and the dual specificity phosphatases (DUSP) [137,142,146]. In this disease model, Notch controls tumor inflammation and progression [82,147] by providing a permissive microenvironment [82] in a non-cell-autonomous way. For example, *NOTCH1* deletion in keratinocytes results in the loss of skin barrier integrity, with the consequent increase of thymic stromal lymphopoietin (TSLP) expression by suprabasal keratinocytes that exhibit a potent proliferative effect on B-lymphopoiesis [82,148]. Furthermore, in a murine model of skin carcinogenesis, the tumor developing role of the loss of Notch signaling correlates with high levels of Wnt ligands and the subsequent increase in β -catenin signaling. Loss-of-function mutations in *NOTCH* lead to an impaired balance of tumor-protective/tumor-promoting inflammation by reducing the proinflammatory cytokine TSLP. TSLP allows the accumulation of CD11b⁺Gr1⁺ myeloid cells, which in turn, promote tumor growth by secreting Wnt ligands [149].

Among the non-SCC cancers, the tumor suppressor role of Notch signaling was described in hepatocellular carcinoma (HCC) [150] and glioma tumors [151]. In an *Rb*, *p107*, and *p130* triple-knockout (TKO) HCC model, transcriptional enrichment analysis of HCC cells showed the activation of pathways associated with Notch1-4 signaling and genes that activate canonical oncogenic signals, such as *Wnt*, *p38*, *Ras*, and *MAPK* [150]. Consistently, Notch inhibition with GSI DAPT accelerates tumor progression, while the overexpression of N1-ICD in cell lines derived from TKO tumors protects from tumor growth [150]. These observations indirectly confirm clinical HCC data, wherein the expression of the Notch target gene *HES1* correlates with a median OS of 43.7 months compared with 9.3 months, for those with low *HES1* expression [150,152]. However, two recent studies challenged these results and suggested the opposite role for Notch signaling in HCC progression [153,154]. Similar to that in the TKO HCC model, in a *delTP53* forebrain glioma tumor mouse, *NOTCH1*, *NOTCH2*, or *RB1P* knockout accelerates tumor progression, in part, by the downregulation of *HES5* [155,156]. Interestingly *NOTCH1-4* loss-of-function mutations have been identified in 10–31% and 7% of grade II and III glioma tumors, respectively [151,157,158].

In other cancer subtypes, such as pancreatic ductal adenocarcinoma (PDAC) or myeloid leukemia, the role of NOTCH is still not completely determined [95,109,138]. Genetic loss of *NCSTN* and the chemical inhibition of the γ -secretase complex in murine bone marrow or cord

blood cells induce a hematopoietic phenotype similar to that of chronic myelomonocytic leukemia (CMML), with the aberrant accumulation of granulocyte/monocyte progenitors and extramedullary hematopoiesis [159]. Transcriptome analysis shows that NOTCH regulates a myelomonocytic gene signature through the downregulation of transcription factors *PU.1* and *C/EBP α* by *HES1* in early multipotential progenitor cells. Moreover, landscape studies have identified somatic heterozygous mutations in Notch pathway genes, such as *NCSTN*, *APH1*, *MAML1*, and *NOTCH2*, in 12% of CMML patients [159]. In acute myeloid leukemia (AML), the role of NOTCH is less clear. Most pieces of evidence suggest that Notch negatively regulates disease progression [160,161] through a cross-talk with the tumor microenvironment. On the other hand, an overactivated β -catenin pathway, due to a gain-of-function mutation, leads to Jag1 expression in mouse osteoblasts, inducing malignant changes through a NOTCH cell-autonomous effect in hematological myeloid progenitors; the genetic or pharmacological inhibition of NOTCH reduces the development of myeloid malignancies, supporting the pathogenic role of Notch pathway in this disease [162].

7. Targeting Notch Trafficking

While Notch signaling is regulated by enzymatic processes that are involved in small molecule inhibition, multiple roadblocks have been encountered in the translation of these drugs to a clinical setting; therefore, this has not been accomplished yet. Several studies in the literature have described these molecules [163–165] and strategies. Here, for simplicity, we focus on the approaches altering Notch trafficking (Table 1).

Table 1. Active compounds that target Notch trafficking.








Chemical Structure	Class	Compound	Activity on Notch Trafficking	Ref.
	Antiarrhythmic class IV	Bepridil	Ion flux modulation	[84]
	Antimalarial	Chloroquine	Endosomal trafficking impairment	[166]
	HDAC6 inhibitors	Tubacin	Endosomal trafficking impairment	[167]
	POFUT1 analogs	Compounds 9, 10, and 11	EGF-fucosylation inhibition	[168]

Table 1. Cont.

Chemical Structure	Class	Compound	Activity on Notch Trafficking	Ref.
	PSEN1 inhibitors	MRK-560	GS complex inhibition	[169]
	SERCA inhibitors	Thapsigargin Casearin J CAD204520	Ion flux modulation	[170]
	ZIP7 inhibitors	NVS-ZP7-4	Ion flux modulation	[171]

As described above, a furin-like protease (S1) processes an immature NOTCH form, in the ER/Golgi compartment, into a non-covalent heterodimer, that is subsequently expressed on the surface of cells [36] (Figure 1). In 1999, Goran Periz and Mark E. Fortini described that this process may be disrupted in the presence of a defective Ca^{2+} -ATPase function in a *Drosophila* model. the loss of function of the *Drosophila* SERCA homologous gene *Ca-P60A* disrupts the proper synthesis, folding, and trafficking of the NOTCH receptor in the ER/Golgi compartment. Consistently, in *Drosophila* S2 lines, the treatment with SERCA inhibitors, such as thapsigargin and cyclopiazonic acid (CPA), reduces the amount of NOTCH protein on the cell plasma membrane [172]. Subsequently, Roti and Stegmaier confirmed these observations in a mammalian model of *NOTCH1* mutated T-ALL by integrating *NOTCH* gain- and loss-of-function screening approaches to identify inhibitors of oncogenic *NOTCH1* signatures or enhancer of *NOTCH1* HD mutant *L1601PΔP* activity [170]. the SERCA inhibitors and ion flux modulators scored highly in the screens, suggesting the feasibility of alternative approaches to enzyme inhibitors to suppress oncogenic *NOTCH1*.

Thapsigargin, a well-known anticancer agent [173], is extracted from the umbelliferous Mediterranean plant *Thapsia garganica*. Thapsigargin blocks SERCA in a Ca^{2+} free state through an irreversible lipophilic interaction in a so-called “dead-end” inactive state with low Ca^{2+} affinity [174,175]. SERCA inhibition impairs the trafficking of mutated NOTCH1 receptors from the ER to the cell surface, leading to the accumulation of aberrant N1-FL in the ER/Golgi compartment and the subsequent reduction of N1-TM, N1-ICD, and NOTCH1 target genes. NOTCH1 suppression causes cell cycle arrest and inhibition of leukemia growth in vitro in T-ALL xenografts and in a *Drosophila* intestinal stem cell model [170]. Importantly, thapsigargin preferentially targets mutated NOTCH1 proteins, as shown by its antileukemic effect and the lack of gastrointestinal toxicity in a human T-ALL xenograft murine model treated with 0.4 mg/kg thapsigargin, in sharp contrast with previous experiences with GSI [176]. However, translating the effects of thapsigargin into a clinical setting is limited by the generic effects on the SERCA pump, particularly on the cardiac isoform SERCA2a [177].

To overcome the limitations associated with the non-cell-specific effects of thapsigargin, Denmeade’s group developed a pro-drug approach to deliver thapsigargin only to cancer cells [178–180]. Following this enzymatic-based approach, Roti and colleagues leveraged the dependency of ALL on folic acid (FA) metabolism [181]. They first demonstrated that folate receptor 2 is aberrantly expressed in T-ALL, and then, they used it as an endocytic carrier for conjugated probes. Next, they showed that the conjugable alcohol derivative of thapsigargin, 8-*O*-debutanoyl-thapsigargin, inhibits NOTCH1 in a way that is similar to the effect of thapsigargin observed in T-ALL models. Notably, 8-*O*-debutanoyl-thapsigargin preserved a selective activity against mutant over NOTCH1 wild-type T-ALL. Subsequently, they connected the carboxylate of folic acid to the C8-alcohol of 8-*O*-debutanoyl-thapsigargin via a cleavable ester linkage to generate JQ-FT. JQ-FT was 150 times more tolerable in mice than unconjugated thapsigargin and exerted an anti-leukemic effect in a preclinical NOTCH1 mutated T-ALL in vivo model [181]. This approach sets the ground for the development of inhibitors with dual selectivity: cancer over normal cells and NOTCH1 mutated over wild-type targets.

A different strategy that can be used to overcome the thapsigargin limitations due to cardiac effects is to search for new small molecules that share a therapeutic index similar to that of thapsigargin, but which have a safer toxicity profile. Beyond the few SERCA inhibitors with an unclear activity against Notch trafficking, such as curcumin [182–184] and CXL017 [185,186], the tricyclic clerodane diterpene Casearin J (CJ) was extensively explored as a NOTCH1 inhibitor in T-ALLs [187,188]. CJ affects Notch trafficking, reducing the cell surface expression of N1-TM and preventing the formation of cleaved N1-ICD modules, which results in the transcriptional suppression of Notch1 target genes, such as *MYC* and *HES1*. De Ford and colleagues also showed that CJ was more active against HD-mutated T-ALL cells than against a cell line carrying a NOTCH1 juxtamembrane mutation, such as Jurkat [188]. Although this does not exclude the role of CJ on NOTCH1 wild-type cells, it confirms that T-ALL is sensitive to Ca^{2+} -ATPase suppression, further supporting the need to explore SERCA inhibitors with binding sites different from that of thapsigargin. Toward this goal, we completed an analysis of a small molecule screening of 191,000 compounds active on P-type ATPases; (4-[2-[2-[3-propyl-6-(trifluoromethoxy)-1H-indol-2-yl]-1-piperidyl]ethyl]morpholine) dihydrochloride inhibitor, CAD204520, showed favorable pharmacokinetics and dynamics profiles [189]. Both in preclinical and in vivo models, CAD204520 was well-tolerated without causing overt cardiac toxicity, while suppressing T-ALL leukemia growth. As CAD204520 binds to SERCA in residues different from the one occupied by thapsigargin, we may argue that the SERCA binding site influences the Ca^{2+} fluxes. This hypothesis is in line with the recent work of Sehgal and colleagues, which showed that SERCA inhibition may be achieved without triggering measurable changes in Ca^{2+} levels [190].

The original GE-HTS screen also led to the identification of the FDA-approved ion flux Ca^{2+} modulator, bepridil, a class IV antiarrhythmic drug [191] with limited toxic effects. This observation was leveraged to challenge a repurposing effort in NOTCH1 mutated cancers. Bepridil showed preclinical activity in T-ALL [192] and CLL [84]. Similar to previous data on thapsigargin, bepridil impaired the trafficking of NOTCH1 proteins, resulting in the suppression of N-TM peptides and,

consequently, the N1-ICD fragments in CLL. Interestingly, bepridil suppresses NOTCH1 activation in both cell-autonomous and non-autonomous conditions [193]. Consistently, ex vivo and in vivo studies confirmed that bepridil reduces CD45⁺CD19⁺CD5⁺ leukemic cells in the spleen and lymph nodes of mice. Interestingly, the anti-leukemic effects of bepridil were independent of the *IGHV* mutational status, *SF3B1*, *TP53* deletion, *ZAP70* expression, and chromosomal abnormalities, such as 17p, 11q deletions, or 13q trisomy. Bepridil-treated mice showed no differences in body weight and no signs of gastrointestinal toxicities, further suggesting a preferential activity against NOTCH1 over NOTCH2. The number of goblet cells in the gut epithelium was preserved according to the PAS (Periodic acid–Schiff) staining distribution, suggesting a lack of NOTCH2 on-target effect [84].

A recent study by Fortini and colleagues showed that Notch trafficking can be impaired through the disruption of zinc (Zn²⁺) homeostasis in a *Drosophila* model; in a mutagenesis screen targeting genes controlling Notch trafficking, they demonstrated that loss-of-function mutations in the *Catsup* gene, a *Drosophila* orthologue of mammalian zinc transporter *ZIP7*, induced the accumulation of NOTCH protein in the ER/Golgi, and consequently impaired the signaling downstream to S1 cleavage. They also showed that the alteration of Zn²⁺ homeostasis led to increased ER stress levels and the activation of the unfolded protein response (UPR) [194]. Based on these premises, Nolin and colleagues completed a large, small molecule screening to identify *ZIP7* modulators [171]. The authors showed that NVS-ZP7-1 and its derivative, NVS-ZP7-3, target the Notch pathway, as shown by the suppression of the Notch target genes *Deltex E3 Ubiquitin Ligase 1 (DTX1)* and *NOTCH3* by a mechanism resembling that of one of the SERCA inhibitors. Interestingly, they demonstrated an enhanced activity against the TALL-1 cell line that carries a *NOTCH3* activating mutation, suggesting that the disruption of ion homeostasis may cause a unique therapeutic index in wild-type vs. mutant. In contrast to our most recent work [189], the NVS-ZP7 small-molecule series trigger the activation of UPR. This stress effect, mediated by an accumulation of Zn²⁺ [171] in the ER, is similar to that caused by thapsigargin, urging further studies to assess the potential toxicities of this approach.

Post-translational O-glycans modification events occurring in the EGF domains are emerging targets for therapeutic intervention in NOTCH-dependent diseases. POFUT1 modulators represent the most successful example. As mentioned above, POFUT1 is responsible for the transfer of O-fucose to EGF repeats with an O-fucose consensus sequence. O-fucose modifications subsequently remain substrates for GlcNAc addition by enzymes of the Fringe family. Schneider and colleagues generated a series of analogs of GDP-fucose derivatives and tested their inhibitory effect on Notch signaling in transgenic Zebrafish Tg(Tp1bglob:eGFP)^{um14} embryos expressing a *NOTCH* reporter transgene (GFP under the control of elements responsive to N-ICD) [168]. In this series, compounds **3**, **4**, and **6** with C-6 ethynyl, ethenyl, and OH substituents, respectively, showed the greatest Notch inhibitory activity. The corresponding peracetylated fucose analogs (compounds **10** and **11** corresponding to compounds **3** and **4**) used for in vitro mammalian studies were transferred by POFUT1 onto NOTCH EGF repeats, replacing natural fucose on the polypeptides and suggesting a mechanism of Notch signaling disruption, rather than an inhibitory effect on the activity of fucosyltransferase or Fringe N-acetylglucosaminyltransferase. Compounds **10** and **11** abolished Notch signaling in a Dll1-4-Notch1 or Dll4-Notch2 reporter assay by disrupting the ligand-receptor binding but, intriguingly, caused no significant effects on Jag1-induced Notch signaling. Moreover, mutations of O-fucose residues on T311 in EGF8 and T466 in EGF12 rescued Notch activation in the aforesaid experimental model, suggesting that the presence of the fucose analogs interferes with NOTCH binding to Dll ligands. Collectively, these data pioneered a novel strategy to suppress Notch signaling by altering NOTCH glycosylation and present the first in class Delta-specific inhibitors of NOTCH1.

8. Targeting the Endosomal Compartment

Targeting endosomal trafficking appears as an emerging approach in tumors in which NOTCH is hyper expressed as a consequence of mechanisms other than mutations [195]. For example, in glioblastoma, components of the plasminogen activator (PA) system, such as urokinase-type

plasminogen activator (uPA) and its receptor (uPAR), play a critical role in tumor progression and metastasis [196], regulating the proteolytic degradation of the extracellular matrix (ECM) [197], promoting tumor cell invasion, migration, and homing to distant organs [198]. Single (uPA, uPAR) or simultaneous (U2) genetic suppression of this multifunctional system reduces glioma cell invasion by inhibiting NOTCH1 cleavage and mRNA expression, as shown in commercially available (U251 MG) and xenograft-derived glioblastoma cell lines (5310 and 4910). Sequentially, *NOTCH1* downregulation reduces uPA expression, causing an anti-cancer positive feedback loop. Transcriptional suppression of uPA/uPAR accrues NOTCH1 accumulation in lysosomes, as shown in co-localization studies, suggesting that the disruption of the uPA/uPAR axis may, in turn, attenuate NOTCH1 receptor cleavage, signaling, and endosomal trafficking [199].

Another approach is by acting on the post-translational modifications required by NOTCH for trafficking or by acting on the endosomes that transport these receptors [65,200,201]. Histone deacetylases (HDACs), for example, control endosomal trafficking [202,203] by deacetylating histone or non-histone proteins, such as α -tubulin or Hsp-90 [204]. Consistently, trichostatin A, a pan HDAC inhibitor, reduces the level of N3-FL, N3-TM, and N3-ICD in two different human T-ALL cell lines and in different patient-derived xenografts (PDX), causing the transcriptional suppression of NOTCH3 target genes, such as pre-T cell receptor α (*pT α*), complement receptor (CR) 2 and *DTX1* [167]. Furthermore, NOTCH3 is retained in the endolysosomes upon treatment, as shown in immunofluorescence co-localization studies. Interestingly, genetic and enzymatic silencing of HDAC6 recapitulated these effects, suggesting that the selective suppression of HDAC6 may represent an alternative therapeutic approach in Notch3-dependent malignancies, such as T-ALL and glioma [167,205]. Collectively, these results support the development of selective approaches to disrupt the vesicular trafficking of NOTCH receptors.

9. Improving the GS Complex Inhibition Strategy

Several works have reviewed the role of γ -secretase in *NOTCH* mutated cancers [163,165,206]. However, few of them suggested the role of PSEN1 and PSEN2 in controlling γ -secretase cleavages in lysosomes, endosomes [60,72,207], or in the ER [208], suggesting that targeting PSEN complexes may lead to altered NOTCH, independently of the role of these proteins on S3 cleavage. Habets and colleagues showed that PSEN1 expression was higher than that of PSEN2 in T-ALL cell lines and patient samples, confirming previous evidence [209,210]. *Psen1*-knockout murine cells lack NOTCH expression, while *Psen2*-deficient cells maintain an adequate level of Notch signaling. These results support the hypothesis that PSEN1 selective inhibition may possess clinical activity in T-ALL. Treatment with the PSEN1 inhibitor MRK-560 decreases the leukemia burden and increases the overall survival in T-ALL patient-derived xenografts in vivo, without causing gastrointestinal toxicity or decreasing the normal T-cell development [169]. The lack of side effects may be explained by the compensatory activation of PSEN2 in the gastrointestinal tract and in developing T-cells [169]. These data also suggest that similar to SERCA inhibition, PSEN1 isoform-specific disruption preferentially affects mutated proteins over wild-type ones, overcoming the limitations associated with the first generation of GSIs [211,212].

A commonly used strategy to rescue GSI from their clinical outcome is the development of drug–drug combinations using anti-cancer [213] or anti-inflammatory agents [214]. The association of two potential anti-NOTCH agents has more rarely been attempted, given the risk of increased toxicity. Nevertheless, in a recent work, chloroquine (CQ), an autophagy inhibitor with known anti-cancer activity [166,215], enhanced the effect of GSI in *PTEN* wild-type T-ALL cell lines [166]. CQ reduces N-TM expression by altering the endosome-recycling of the protein. The few NOTCH proteins on the surface of cells remain as substrates for GSI inhibition. Overall, the data support the ongoing development of selective GSIs or alternative combination approaches for *NOTCH1* mutant T-ALL.

10. Conclusions

Given the high frequency of activating *NOTCH1* mutations in cancers, especially in T-ALL, the inhibition of the γ -secretase complex has represented a rational target to hijack the ligand-independent release of N-ICD for many years. Initial efforts attempted to repurpose GSIs, originally developed for Alzheimer's disease [212,216], in relapsed/refractory T-ALL. However, only a few experiments reported therapeutic success [217–219]; for example, GSI 906024 developed by Bristol-Myers Squibb [220]. The CA216002 trial demonstrated the safety and tolerability of BMS-906024 administered weekly (4–6 mg) to 25 pediatric patients with T-ALL or T-cell lymphoblastic lymphoma [219]. Half of the patients reported, at least, a 50% reduction in bone marrow blasts, including a complete and a partial response. Despite these few encouraging results, the majority of drugs have not successfully passed clinical trials owing to toxicity secondary to non-specific proteolysis and a lack of therapeutic window across receptor isoforms (NOTCH1-4), and the alleles status (wild-type vs. mutated) [221]. Hence, given the clinical failure of first-generation GSIs [212], it is unlikely that such drugs will be further pursued as single agents. This is not the case for the selective PSEN1 inhibitor MRK-560, that demonstrated inhibition of mutant NOTCH1 processing and a decrease in the leukemia burden without causing gastrointestinal toxicity in T-ALL PDX in vivo. Similarly, in an orthotopic model of breast cancer treated with the monoclonal antibodies 10C11 and 2H6 targeting NCSTN, no histological evidence of goblet cell hyperplasia was detected, while these effects were evident in a GSI-treated arm [222]. Unfortunately, the therapeutic index of emerging NCSTN small molecule inhibitors, such as cowanin, for wild-type vs. mutant has not been tested yet [223]. Nevertheless, these encouraging results suggest that the selective disruption of members of the γ -secretase complex may preferentially affect mutated proteins, overcoming the innate limitations associated with pan γ -secretase inhibition.

Appropriate NOTCH subcellular localization is crucial and provides the time and space context for its activation. The succession of "S" cleavages is tightly regulated and, consequently, the subcellular mislocalization of NOTCH proteins might represent an attractive strategy for therapeutic interventions. We and others have been pioneers in the research of this strategy, identifying SERCA as a liable regulator of Notch signaling [170,172]. A recent study demonstrated that the disruption of *Drosophila* SERCA and Orai, a plasma membrane Ca^{2+} channel that mediates store-operated calcium entry (SOCE), produces three distinct outcomes in ER Ca^{2+} levels. While weak Ca^{2+} preferentially affects the Wnt/Wingless (Wg) pathway, a more dramatic SERCA disruption affects the Hippo and Notch [224] signaling pathways, suggesting that Wnt-driven cancers may be the most sensitive to SERCA suppression. However, this level of granularity of ER Ca^{2+} control observed in experimental conditions may be difficult to achieve using thapsigargin, raising legitimate concerns regarding the effects caused by the abrogation of SERCA on the Hippo tumor suppressor pathway [224]. Nevertheless, we demonstrated that acute Ca^{2+} related toxicities or secondary consequences associated with the activation of UPR, associated with pan SERCA inhibition, might be overcome by the identification of new Ca^{2+} ATPase binding targets, to guide innovative drug development [189]. Moreover, in our experience, chronic exposure to SERCA inhibitors in several in vivo models did not cause a pro-tumorigenic effect [170,181]. Here, we can propose two hypotheses. First, our previous studies were too short in time to suppress Hippo signaling, and second, depending on the cell context, Hippo may have a tumor suppressor or an oncogenic role. Knockdown of the transducer yes-associated protein (YAP), a key modulator of Hippo signaling, decreased leukemia cell proliferation and enhanced cell apoptosis in T-ALL [225], suggesting that, in this context, Hippo might act as an oncogene. Although limited data have been reported from the clinical trial NCT01777594, no evidence of secondary tumors has been reported in patients treated with a thapsigargin derivative [179,180].

While these innovative approaches are yet to be translated into clinical practice, targeting Notch trafficking is within reach. For example, chloroquine, a well-known 4-aminoquinoline antimalarial drug, interferes with intracellular trafficking and processing of oncogenic NOTCH1 [166]. Due to

the narrow therapeutic index, it is unlikely that this drug will affect highly proliferating cells as a single drug, but it would be promising to use it in combination with standard chemotherapy agents.

In conclusion, while GSI has dominated the arena of potential NOTCH inhibitors in the last two decades, new approaches targeting Notch trafficking are rapidly emerging. We expect that these strategies may be further explored for cancers in which oncogenic transformation requires sequential activations across different cellular compartments.

Author Contributions: Conception and design: L.P., C.S., and G.R.; writing, review, and/or revision of the manuscript: L.P., C.S., and G.R.; study supervision: G.R. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by an AIRC Start-up Investigator Grant (n. 17107 G.R.), Fondazione Cariparma (3576/2017, 0180/2018 G.R.), Leukemia Research Foundation (G.R.), Fondazione Grande Ale Onlus (G.R.), and Feliciani Ferretti Fellowship (L.P.). C.S. is a Fondazione Veronesi post-doctoral fellow.

Acknowledgments: The authors thank Pamela Criscuoli for her support and the Hematology and BMT unit at the University of Parma.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Dexter, J.S. the analysis of a case of continuous variation in *Drosophila* by a study of its linkage relations. *Am. Nat.* **1914**, *48*, 712–758. [[CrossRef](#)]
2. Morgan, T.H. the Origin of Nine Wing Mutations in *Drosophila*. *Science* **1911**, *33*, 496–499. [[CrossRef](#)] [[PubMed](#)]
3. Morgan, T.H. Sex Limited Inheritance in *Drosophila*. *Science* **1910**, *32*, 120–122. [[CrossRef](#)]
4. Morgan, T.H. the Theory of the Gene. *Am. Nat.* **1917**, *51*, 513–544. [[CrossRef](#)]
5. Kidd, S.; Kelley, M.R.; Young, M.W. Sequence of the notch locus of *Drosophila melanogaster*: Relationship of the encoded protein to mammalian clotting and growth factors. *Mol. Cell Biol.* **1986**, *6*, 3094–3108. [[CrossRef](#)]
6. Wharton, K.A.; Johansen, K.M.; Xu, T.; Artavanis-Tsakonas, S. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. *Cell* **1985**, *43*, 567–581. [[CrossRef](#)]
7. Bray, S.J. Notch signalling in context. *Nat. Rev. Mol. Cell. Biol.* **2016**, *17*, 722–735. [[CrossRef](#)]
8. Gridley, T. Notch signaling and inherited disease syndromes. *Hum. Mol. Genet.* **2003**, *12*, R9–R13. [[CrossRef](#)]
9. Takebe, N.; Miele, L.; Harris, P.J.; Jeong, W.; Bando, H.; Kahn, M.; Yang, S.X.; Ivy, S.P. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. *Nat. Rev. Clin. Oncol.* **2015**, *12*, 445–464. [[CrossRef](#)]
10. Lai, E.C. Notch signaling: Control of cell communication and cell fate. *Development* **2004**, *131*, 965–973. [[CrossRef](#)]
11. Sanchez-Irizarry, C.; Carpenter, A.C.; Weng, A.P.; Pear, W.S.; Aster, J.C.; Blacklow, S.C. Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. *Mol. Cell Biol.* **2004**, *24*, 9265–9273. [[CrossRef](#)]
12. Kopan, R.; Ilagan, M.X. the canonical Notch signaling pathway: Unfolding the activation mechanism. *Cell* **2009**, *137*, 216–233. [[CrossRef](#)] [[PubMed](#)]
13. Gordon, W.R.; Roy, M.; Vardar-Ulu, D.; Garfinkel, M.; Mansour, M.R.; Aster, J.C.; Blacklow, S.C. Structure of the Notch1-negative regulatory region: Implications for normal activation and pathogenic signaling in T-ALL. *Blood* **2009**, *113*, 4381–4390. [[CrossRef](#)] [[PubMed](#)]
14. Borggreffe, T.; Oswald, F. the Notch signaling pathway: Transcriptional regulation at Notch target genes. *Cell Mol. Life Sci.* **2009**, *66*, 1631–1646. [[CrossRef](#)] [[PubMed](#)]
15. Okajima, T.; Irvine, K.D. Regulation of notch signaling by o-linked fucose. *Cell* **2002**, *111*, 893–904. [[CrossRef](#)]
16. Acar, M.; Jafar-Nejad, H.; Takeuchi, H.; Rajan, A.; Ibrani, D.; Rana, N.A.; Pan, H.; Haltiwanger, R.S.; Bellen, H.J. Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is required for Notch signaling. *Cell* **2008**, *132*, 247–258. [[CrossRef](#)]

17. Takeuchi, H.; Kantharia, J.; Sethi, M.K.; Bakker, H.; Haltiwanger, R.S. Site-specific O-glycosylation of the epidermal growth factor-like (EGF) repeats of notch: Efficiency of glycosylation is affected by proper folding and amino acid sequence of individual EGF repeats. *J. Biol. Chem.* **2012**, *287*, 33934–33944. [[CrossRef](#)]
18. Rebay, I.; Fleming, R.J.; Fehon, R.G.; Cherbas, L.; Cherbas, P.; Artavanis-Tsakonas, S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: Implications for Notch as a multifunctional receptor. *Cell* **1991**, *67*, 687–699. [[CrossRef](#)]
19. Wang, Y.; Shao, L.; Shi, S.; Harris, R.J.; Spellman, M.W.; Stanley, P.; Haltiwanger, R.S. Modification of epidermal growth factor-like repeats with O-fucose. Molecular cloning and expression of a novel GDP-fucose protein O-fucosyltransferase. *J. Biol. Chem.* **2001**, *276*, 40338–40345. [[CrossRef](#)]
20. Luo, Y.; Haltiwanger, R.S. O-fucosylation of notch occurs in the endoplasmic reticulum. *J. Biol. Chem.* **2005**, *280*, 11289–11294. [[CrossRef](#)]
21. Takeuchi, H.; Yu, H.; Hao, H.; Takeuchi, M.; Ito, A.; Li, H.; Haltiwanger, R.S. O-Glycosylation modulates the stability of epidermal growth factor-like repeats and thereby regulates Notch trafficking. *J. Biol. Chem.* **2017**, *292*, 15964–15973. [[CrossRef](#)] [[PubMed](#)]
22. Sethi, M.K.; Buettner, F.F.; Ashikov, A.; Krylov, V.B.; Takeuchi, H.; Nifantiev, N.E.; Haltiwanger, R.S.; Gerardy-Schahn, R.; Bakker, H. Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glycosylated epidermal growth factor repeats of notch. *J. Biol. Chem.* **2012**, *287*, 2739–2748. [[CrossRef](#)] [[PubMed](#)]
23. Urata, Y.; Saiki, W.; Tsukamoto, Y.; Sago, H.; Hibi, H.; Okajima, T.; Takeuchi, H. Xylosyl Extension of O-Glucose Glycans on the Extracellular Domain of NOTCH1 and NOTCH2 Regulates Notch Cell Surface Trafficking. *Cells* **2020**, *9*, 1220. [[CrossRef](#)] [[PubMed](#)]
24. Cui, Q.; Xing, J.; Gu, Y.; Nan, X.; Ma, W.; Chen, Y.; Zhao, H. GXYLT2 accelerates cell growth and migration by regulating the Notch pathway in human cancer cells. *Exp. Cell Res.* **2019**, *376*, 1–10. [[CrossRef](#)]
25. Hicks, C.; Johnston, S.H.; diSibio, G.; Collazo, A.; Vogt, T.F.; Weinmaster, G. Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2. *Nat. Cell Biol.* **2000**, *2*, 515–520. [[CrossRef](#)]
26. Panin, V.M.; Papayannopoulos, V.; Wilson, R.; Irvine, K.D. Fringe modulates Notch-ligand interactions. *Nature* **1997**, *387*, 908–912. [[CrossRef](#)]
27. Haines, N.; Irvine, K.D. Glycosylation regulates Notch signalling. *Nat. Rev. Mol. Cell Biol.* **2003**, *4*, 786–797. [[CrossRef](#)]
28. Takeuchi, H.; Schneider, M.; Williamson, D.B.; Ito, A.; Takeuchi, M.; Handford, P.A.; Haltiwanger, R.S. Two novel protein O-glycosyltransferases that modify sites distinct from POGLUT1 and affect Notch trafficking and signaling. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E8395–E8402. [[CrossRef](#)]
29. Blaumueller, C.M.; Qi, H.; Zagouras, P.; Artavanis-Tsakonas, S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. *Cell* **1997**, *90*, 281–291. [[CrossRef](#)]
30. Rand, M.D.; Grimm, L.M.; Artavanis-Tsakonas, S.; Patriub, V.; Blacklow, S.C.; Sklar, J.; Aster, J.C. Calcium depletion dissociates and activates heterodimeric notch receptors. *Mol. Cell Biol.* **2000**, *20*, 1825–1835. [[CrossRef](#)]
31. Logeat, F.; Bessia, C.; Brou, C.; LeBail, O.; Jarriault, S.; Seidah, N.G.; Israel, A. the Notch1 receptor is cleaved constitutively by a furin-like convertase. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 8108–8112. [[CrossRef](#)] [[PubMed](#)]
32. Shen, M.M. Nodal signaling: Developmental roles and regulation. *Development* **2007**, *134*, 1023–1034. [[CrossRef](#)] [[PubMed](#)]
33. Schier, A.F.; Shen, M.M. Nodal signalling in vertebrate development. *Nature* **2000**, *403*, 385–389. [[CrossRef](#)] [[PubMed](#)]
34. Watanabe, K.; Nagaoka, T.; Lee, J.M.; Bianco, C.; Gonzales, M.; Castro, N.P.; Rangel, M.C.; Sakamoto, K.; Sun, Y.; Callahan, R.; et al. Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. *J. Cell Biol.* **2009**, *187*, 343–353. [[CrossRef](#)] [[PubMed](#)]
35. Ntziachristos, P.; Lim, J.S.; Sage, J.; Aifantis, I. From fly wings to targeted cancer therapies: a centennial for notch signaling. *Cancer Cell* **2014**, *25*, 318–334. [[CrossRef](#)]
36. Brou, C.; Logeat, F.; Gupta, N.; Bessia, C.; LeBail, O.; Doedens, J.R.; Cumano, A.; Roux, P.; Black, R.A.; Israël, A. a novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. *Mol. Cell* **2000**, *5*, 207–216. [[CrossRef](#)]

37. Mumm, J.S.; Schroeter, E.H.; Saxena, M.T.; Griesemer, A.; Tian, X.; Pan, D.J.; Ray, W.J.; Kopan, R. a ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. *Mol. Cell* **2000**, *5*, 197–206. [[CrossRef](#)]
38. Parks, A.L.; Klueg, K.M.; Stout, J.R.; Muskavitch, M.A. Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. *Development* **2000**, *127*, 1373–1385.
39. van Tetering, G.; van Diest, P.; Verlaan, I.; van der Wall, E.; Kopan, R.; Vooijs, M. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. *J. Biol. Chem.* **2009**, *284*, 31018–31027. [[CrossRef](#)]
40. Bozkulak, E.C.; Weinmaster, G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. *Mol. Cell Biol.* **2009**, *29*, 5679–5695. [[CrossRef](#)]
41. Schroeter, E.H.; Kisslinger, J.A.; Kopan, R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. *Nature* **1998**, *393*, 382–386. [[CrossRef](#)] [[PubMed](#)]
42. Struhl, G.; Greenwald, I. Presenilin is required for activity and nuclear access of Notch in Drosophila. *Nature* **1999**, *398*, 522–525. [[CrossRef](#)] [[PubMed](#)]
43. De Strooper, B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. *Neuron* **2003**, *38*, 9–12. [[CrossRef](#)]
44. Haapasalo, A.; Kovacs, D.M. the many substrates of presenilin/ γ -secretase. *J. Alzheimers Dis* **2011**, *25*, 3–28. [[CrossRef](#)] [[PubMed](#)]
45. Kimberly, W.T.; LaVoie, M.J.; Ostaszewski, B.L.; Ye, W.; Wolfe, M.S.; Selkoe, D.J. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 6382–6387. [[CrossRef](#)] [[PubMed](#)]
46. Wu, L.; Aster, J.C.; Blacklow, S.C.; Lake, R.; Artavanis-Tsakonas, S.; Griffin, J.D. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. *Nat. Genet.* **2000**, *26*, 484–489. [[CrossRef](#)]
47. Jarriault, S.; Brou, C.; Logeat, F.; Schroeter, E.H.; Kopan, R.; Israel, A. Signalling downstream of activated mammalian Notch. *Nature* **1995**, *377*, 355–358. [[CrossRef](#)]
48. Gerhardt, D.M.; Pajcini, K.V.; D’Altri, T.; Tu, L.; Jain, R.; Xu, L.; Chen, M.J.; Rentschler, S.; Shestova, O.; Wertheim, G.B.; et al. the Notch1 transcriptional activation domain is required for development and reveals a novel role for Notch1 signaling in fetal hematopoietic stem cells. *Genes Dev.* **2014**, *28*, 576–593. [[CrossRef](#)]
49. Seugnet, L.; Simpson, P.; Haenlin, M. Requirement for dynamin during Notch signaling in Drosophila neurogenesis. *Dev. Biol.* **1997**, *192*, 585–598. [[CrossRef](#)]
50. Kandachar, V.; Roegiers, F. Endocytosis and control of Notch signaling. *Curr. Opin. Cell Biol.* **2012**, *24*, 534–540. [[CrossRef](#)]
51. Schnute, B.; Troost, T.; Klein, T. Endocytic Trafficking of the Notch Receptor. *Adv. Exp. Med. Biol.* **2018**, *1066*, 99–122. [[CrossRef](#)] [[PubMed](#)]
52. Gupta-Rossi, N.; Six, E.; LeBail, O.; Logeat, F.; Chastagner, P.; Olry, A.; Israël, A.; Brou, C. Monoubiquitination and endocytosis direct gamma-secretase cleavage of activated Notch receptor. *J. Cell Biol.* **2004**, *166*, 73–83. [[CrossRef](#)] [[PubMed](#)]
53. Sorensen, E.B.; Conner, S.D. gamma-secretase-dependent cleavage initiates notch signaling from the plasma membrane. *Traffic* **2010**, *11*, 1234–1245. [[CrossRef](#)]
54. Windler, S.L.; Bilder, D. Endocytic internalization routes required for delta/notch signaling. *Curr Biol.* **2010**, *20*, 538–543. [[CrossRef](#)] [[PubMed](#)]
55. Zerial, M.; McBride, H. Rab proteins as membrane organizers. *Nat. Rev. Mol. Cell Biol.* **2001**, *2*, 107–117. [[CrossRef](#)]
56. Chastagner, P.; Israël, A.; Brou, C. AIP4/Itch regulates Notch receptor degradation in the absence of ligand. *PLoS ONE* **2008**, *3*, e2735. [[CrossRef](#)]
57. Henne, W.M.; Buchkovich, N.J.; Emr, S.D. the ESCRT pathway. *Dev. Cell* **2011**, *21*, 77–91. [[CrossRef](#)]
58. Huotari, J.; Helenius, A. Endosome maturation. *EMBO J.* **2011**, *30*, 3481–3500. [[CrossRef](#)]
59. Yeh, C.-H.; Bellon, M.; Nicot, C. FBXW7: a critical tumor suppressor of human cancers. *Mol. Cancer* **2018**, *17*, 115. [[CrossRef](#)]
60. Pasternak, S.H.; Bagshaw, R.D.; Guiral, M.; Zhang, S.; Ackerley, C.A.; Pak, B.J.; Callahan, J.W.; Mahuran, D.J. Presenilin-1, nicastrin, amyloid precursor protein, and γ -secretase activity are co-localized in the lysosomal membrane. *J. Biol. Chem.* **2003**, *278*, 26687–26694. [[CrossRef](#)]

61. Sakata, T.; Sakaguchi, H.; Tsuda, L.; Higashitani, A.; Aigaki, T.; Matsuno, K.; Hayashi, S. Drosophila Nedd4 regulates endocytosis of notch and suppresses its ligand-independent activation. *Curr. Biol.* **2004**, *14*, 2228–2236. [[CrossRef](#)] [[PubMed](#)]
62. Busseau, I.; Diederich, R.J.; Xu, T.; Artavanis-Tsakonas, S. a member of the Notch group of interacting loci, dextex encodes a cytoplasmic basic protein. *Genetics* **1994**, *136*, 585–596. [[PubMed](#)]
63. Wilkin, M.; Tonggok, P.; Gensch, N.; Clemence, S.; Motoki, M.; Yamada, K.; Hori, K.; Taniguchi-Kanai, M.; Franklin, E.; Matsuno, K. Drosophila HOPS and AP-3 complex genes are required for a Deltex-regulated activation of notch in the endosomal trafficking pathway. *Dev. Cell* **2008**, *15*, 762–772. [[CrossRef](#)]
64. Dell'Angelica, E.C. AP-3-dependent trafficking and disease: the first decade. *Curr. Opin. Cell Biol.* **2009**, *21*, 552–559. [[CrossRef](#)] [[PubMed](#)]
65. Fortini, M.E. Notch signaling: the core pathway and its posttranslational regulation. *Dev. Cell* **2009**, *16*, 633–647. [[CrossRef](#)]
66. Fortini, M.E.; Bilder, D. Endocytic regulation of Notch signaling. *Curr. Opin. Genet. Dev.* **2009**, *19*, 323–328. [[CrossRef](#)]
67. Yamamoto, S.; Charng, W.-L.; Bellen, H.J. Endocytosis and intracellular trafficking of Notch and its ligands. In *Current Topics in Developmental Biology*; Elsevier: Amsterdam, the Netherlands, 2010; pp. 165–200.
68. Troost, T.; Jaeckel, S.; Ohlenhard, N.; Klein, T. the tumour suppressor Lethal (2) giant discs is required for the function of the ESCRT-III component Shrub/CHMP4. *J. Cell Sci.* **2012**, *125*, 763–776. [[CrossRef](#)]
69. Yan, Y.; Deneff, N.; Schüpbach, T. the vacuolar proton pump, V-ATPase, is required for notch signaling and endosomal trafficking in Drosophila. *Dev. Cell* **2009**, *17*, 387–402. [[CrossRef](#)]
70. Lee, J.M.; Petrucelli, L.; Fisher, G.; Ramdath, S.; Castillo, J.; Di Fiore, M.M.; D'Aniello, A. Evidence for D-aspartyl- β -amyloid secretase activity in human brain. *J. Neuropathol. Exp. Neurol.* **2002**, *61*, 125–131. [[CrossRef](#)]
71. Zhang, L.; Song, L.; Terracina, G.; Liu, Y.; Pramanik, B.; Parker, E. Biochemical characterization of the γ -secretase activity that produces β -amyloid peptides. *Biochemistry* **2001**, *40*, 5049–5055. [[CrossRef](#)]
72. Tagami, S.; Okochi, M.; Yanagida, K.; Ikuta, A.; Fukumori, A.; Matsumoto, N.; Ishizuka-Katsura, Y.; Nakayama, T.; Itoh, N.; Jiang, J. Regulation of Notch signaling by dynamic changes in the precision of S3 cleavage of Notch-1. *Mol. Cellular Biol.* **2008**, *28*, 165–176. [[CrossRef](#)] [[PubMed](#)]
73. Artavanis-Tsakonas, S. the molecular biology of the Notch locus and the fine tuning of differentiation in Drosophila. *Trends Genet.* **1988**, *4*, 95–100. [[CrossRef](#)]
74. Pajcini, K.V.; Speck, N.A.; Pear, W.S. Notch signaling in mammalian hematopoietic stem cells. *Leukemia* **2011**, *25*, 1525–1532. [[CrossRef](#)]
75. Gering, M.; Patient, R. Notch signalling and haematopoietic stem cell formation during embryogenesis. *J. Cell. Physiol.* **2010**, *222*, 11–16. [[CrossRef](#)]
76. Bugeon, L.; Taylor, H.B.; Prohazky, F.; Lin, M.I.; Ellis, C.D.; Welsh, N.; Smith, E.; Vargesson, N.; Gray, C.; Renshaw, S.A. the NOTCH pathway contributes to cell fate decision in myelopoiesis. *Haematologica* **2011**, *96*, 1753–1760. [[CrossRef](#)] [[PubMed](#)]
77. Aster, J.C.; Pear, W.S.; Blacklow, S.C. the varied roles of Notch in cancer. *Annu. Rev. Pathol. Mech. Dis.* **2017**, *12*, 245–275. [[CrossRef](#)]
78. Khosla, R.; Vyas, A.K.; Trehanpati, N. Dichotomy of Notch signalling in regulating tumour immune surveillance. *Scand. J. Immunol.* **2019**, *89*, e12744.
79. Shang, Y.; Smith, S.; Hu, X. Role of Notch signaling in regulating innate immunity and inflammation in health and disease. *Protein Cell* **2016**, *7*, 159–174. [[CrossRef](#)]
80. Meurette, O.; Mehlen, P. Notch signaling in the tumor microenvironment. *Cancer Cell* **2018**, *34*, 536–548. [[CrossRef](#)]
81. Delgado-Calle, J.; Anderson, J.; Cregor, M.D.; Hiasa, M.; Chirgwin, J.M.; Carlesso, N.; Yoneda, T.; Mohammad, K.S.; Plotkin, L.I.; Roodman, G.D. Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. *Cancer Res.* **2016**, *76*, 1089–1100. [[CrossRef](#)]
82. Demehri, S.; Turkoz, A.; Kopan, R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. *Cancer Cell* **2009**, *16*, 55–66. [[CrossRef](#)]

83. Stoeck, A.; Lejnine, S.; Truong, A.; Pan, L.; Wang, H.; Zang, C.; Yuan, J.; Ware, C.; MacLean, J.; Garrett-Engele, P.W. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. *Cancer Discov.* **2014**, *4*, 1154–1167. [[CrossRef](#)] [[PubMed](#)]
84. Baldoni, S.; Del Papa, B.; Dorillo, E.; Aureli, P.; De Falco, F.; Rompietti, C.; Sorcini, D.; Varasano, E.; Cecchini, D.; Zei, T.; et al. Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. *Int. J. Cancer* **2018**, *143*, 958–970. [[CrossRef](#)] [[PubMed](#)]
85. Aifantis, I.; Raetz, E.; Buonamici, S. Molecular pathogenesis of T-cell leukaemia and lymphoma. *Nat. Rev. Immunol.* **2008**, *8*, 380–390. [[CrossRef](#)] [[PubMed](#)]
86. Ellisen, L.W.; Bird, J.; West, D.C.; Soreng, A.L.; Reynolds, T.C.; Smith, S.D.; Sklar, J. TAN-1, the human homolog of the *Drosophila notch* gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. *Cell* **1991**, *66*, 649–661. [[CrossRef](#)]
87. Capobianco, A.J.; Zagouras, P.; Blaumueller, C.M.; Artavanis-Tsakonas, S.; Bishop, J.M. Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. *Mol. Cell. Biol.* **1997**, *17*, 6265–6273. [[CrossRef](#)]
88. Pear, W.S.; Aster, J.C.; Scott, M.L.; Hasserjian, R.P.; Soffer, B.; Sklar, J.; Baltimore, D. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. *J. Exp. Med.* **1996**, *183*, 2283–2291. [[CrossRef](#)]
89. Weng, A.P.; Ferrando, A.A.; Lee, W.; Morris, J.P.; Silverman, L.B.; Sanchez-Irizarry, C.; Blacklow, S.C.; Look, A.T.; Aster, J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science* **2004**, *306*, 269–271. [[CrossRef](#)]
90. Malecki, M.J.; Sanchez-Irizarry, C.; Mitchell, J.L.; Histen, G.; Xu, M.L.; Aster, J.C.; Blacklow, S.C. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. *Mol. Cell. Biol.* **2006**, *26*, 4642–4651. [[CrossRef](#)]
91. Sulis, M.L.; Williams, O.; Palomero, T.; Tosello, V.; Pallikuppam, S.; Real, P.J.; Barnes, K.; Zuurbier, L.; Meijerink, J.P.; Ferrando, A.A. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. *Blood J. Am. Soc. Hematol.* **2008**, *112*, 733–740. [[CrossRef](#)]
92. Gupta-Rossi, N.; Le Bail, O.; Gonen, H.; Brou, C.; Logeat, F.; Six, E.; Ciechanover, A.; Israël, A. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. *J. Biol. Chem.* **2001**, *276*, 34371–34378. [[CrossRef](#)] [[PubMed](#)]
93. Thompson, B.J.; Buonamici, S.; Sulis, M.L.; Palomero, T.; Vilimas, T.; Basso, G.; Ferrando, A.; Aifantis, I. the SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. *J. Exp. Med.* **2007**, *204*, 1825–1835. [[CrossRef](#)] [[PubMed](#)]
94. O’Neil, J.; Grim, J.; Strack, P.; Rao, S.; Tibbitts, D.; Winter, C.; Hardwick, J.; Welcker, M.; Meijerink, J.P.; Pieters, R.; et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. *J. Exp. Med.* **2007**, *204*, 1813–1824. [[CrossRef](#)]
95. Gu, Y.; Masiero, M.; Banham, A.H. Notch signaling: Its roles and therapeutic potential in hematological malignancies. *Oncotarget* **2016**, *7*, 29804. [[CrossRef](#)] [[PubMed](#)]
96. Breit, S.; Stanulla, M.; Flohr, T.; Schrappe, M.; Ludwig, W.-D.; Tolle, G.; Happich, M.; Muckenthaler, M.U.; Kulozik, A.E. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. *Blood* **2006**, *108*, 1151–1157. [[CrossRef](#)] [[PubMed](#)]
97. Park, M.J.; Taki, T.; Oda, M.; Watanabe, T.; Yumura-Yagi, K.; Kobayashi, R.; Suzuki, N.; Hara, J.; Horibe, K.; Hayashi, Y. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. *Br. J. Haematol.* **2009**, *145*, 198–206. [[CrossRef](#)]
98. Mansour, M.R.; Sulis, M.L.; Duke, V.; Feroni, L.; Jenkinson, S.; Koo, K.; Allen, C.G.; Gale, R.E.; Buck, G.; Richards, S. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. *J. Clin. Oncol.* **2009**, *27*, 4352. [[CrossRef](#)]
99. Ben Abdelali, R.; Asnafi, V.; Leguay, T.; Boissel, N.; Buzyn, A.; Chevallier, P.; Thomas, X.; Lepretre, S.; Hugué, F.; Vey, N. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. *Blood J. Am. Soc. Hematol.* **2011**, *118*, 5099–5107. [[CrossRef](#)]

100. Pui, J.C.; Allman, D.; Xu, L.; DeRocco, S.; Karnell, F.G.; Bakkour, S.; Lee, J.Y.; Kadesch, T.; Hardy, R.R.; Aster, J.C. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. *Immunity* **1999**, *11*, 299–308. [[CrossRef](#)]
101. Saito, T.; Chiba, S.; Ichikawa, M.; Kunisato, A.; Asai, T.; Shimizu, K.; Yamaguchi, T.; Yamamoto, G.; Seo, S.; Kumano, K. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. *Immunity* **2003**, *18*, 675–685. [[CrossRef](#)]
102. Rossi, D.; Trifonov, V.; Fangazio, M.; Brusca, A.; Rasi, S.; Spina, V.; Monti, S.; Vaisitti, T.; Arruga, F.; Famà, R.; et al. The coding genome of splenic marginal zone lymphoma: Activation of NOTCH2 and other pathways regulating marginal zone development. *J. Exp. Med.* **2012**, *209*, 1537–1551. [[CrossRef](#)] [[PubMed](#)]
103. Kiel, M.J.; Velusamy, T.; Betz, B.L.; Zhao, L.; Weigel, H.G.; Chiang, M.Y.; Huebner-Chan, D.R.; Bailey, N.G.; Yang, D.T.; Bhagat, G.; et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. *J. Exp. Med.* **2012**, *209*, 1553–1565. [[CrossRef](#)] [[PubMed](#)]
104. Nadeu, F.; Clot, G.; Delgado, J.; Martin-Garcia, D.; Baumann, T.; Salaverria, I.; Beà, S.; Pinyol, M.; Jares, P.; Navarro, A. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. *Leukemia* **2018**, *32*, 645–653. [[CrossRef](#)] [[PubMed](#)]
105. Sportoletti, P.; Baldoni, S.; Cavalli, L.; Del Papa, B.; Bonifacio, E.; Ciurnelli, R.; Bell, A.S.; Di Tommaso, A.; Rosati, E.; Crescenzi, B.; et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. *Br. J. Haematol* **2010**, *151*, 404–406. [[CrossRef](#)] [[PubMed](#)]
106. Kridel, R.; Meissner, B.; Rogic, S.; Boyle, M.; Telenius, A.; Woolcock, B.; Gunawardana, J.; Jenkins, C.; Cochrane, C.; Ben-Neriah, S.; et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. *Blood* **2012**, *119*, 1963–1971. [[CrossRef](#)]
107. Fabbri, G.; Rasi, S.; Rossi, D.; Trifonov, V.; Khiabani, H.; Ma, J.; Grunn, A.; Fangazio, M.; Capello, D.; Monti, S. Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation. *J. Exp. Med.* **2011**, *208*, 1389–1401. [[CrossRef](#)]
108. Puente, X.S.; Pinyol, M.; Quesada, V.; Conde, L.; Ordóñez, G.R.; Villamor, N.; Escaramis, G.; Jares, P.; Beà, S.; González-Díaz, M. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature* **2011**, *475*, 101–105. [[CrossRef](#)]
109. South, A.P.; Cho, R.J.; Aster, J.C. The double-edged sword of notch signaling in cancer. In *Seminars in Cell and Developmental Biology*; Elsevier: Amsterdam, the Netherlands, 2012.
110. Rossi, D.; Rasi, S.; Fabbri, G.; Spina, V.; Fangazio, M.; Forconi, F.; Marasca, R.; Laurenti, L.; Brusca, A.; Cerri, M. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. *Blood J. Am. Soc. Hematol.* **2012**, *119*, 521–529. [[CrossRef](#)]
111. Lee, S.y.; Kumano, K.; Nakazaki, K.; Sanada, M.; Matsumoto, A.; Yamamoto, G.; Nannya, Y.; Suzuki, R.; Ota, S.; Ota, Y. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. *Cancer Sci.* **2009**, *100*, 920–926. [[CrossRef](#)]
112. Schmitz, R.; Wright, G.W.; Huang, D.W.; Johnson, C.A.; Phelan, J.D.; Wang, J.Q.; Roulland, S.; Kasbekar, M.; Young, R.M.; Shaffer, A.L. Genetics and pathogenesis of diffuse large B-cell lymphoma. *N. Engl. J. Med.* **2018**, *378*, 1396–1407. [[CrossRef](#)]
113. Boissard, F.; Tosolini, M.; Ligat, L.; Quillet-Mary, A.; Lopez, F.; Fournié, J.-J.; Ysebaert, L.; Poupot, M. Nurse-like cells promote CLL survival through LFA-3/CD2 interactions. *Oncotarget* **2016**, *8*, 52225. [[CrossRef](#)] [[PubMed](#)]
114. Puente, X.S.; Jares, P.; Campo, E. Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions. *Blood* **2018**, *131*, 2283–2296. [[CrossRef](#)] [[PubMed](#)]
115. van Attekum, M.H.; Eldering, E.; Kater, A.P. Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. *Haematologica* **2017**, *102*, 1469–1476. [[CrossRef](#)]
116. Zhang, L.; Yang, J.; Qian, J.; Li, H.; Romaguera, J.E.; Kwak, L.W.; Wang, M.; Yi, Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. *Blood* **2012**, *120*, 3783–3792. [[CrossRef](#)]
117. Silkenstedt, E.; Arenas, F.; Colom-Sanmartí, B.; Xargay-Torrent, S.; Higashi, M.; Giró, A.; Rodríguez, V.; Fuentes, P.; Aulitzky, W.E.; van der Kuip, H.; et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. *J. Exp. Clin. Cancer Res.* **2019**, *38*, 446. [[CrossRef](#)] [[PubMed](#)]

118. Indraccolo, S.; Minuzzo, S.; Masiero, M.; Pusceddu, I.; Persano, L.; Moserle, L.; Reboldi, A.; Favaro, E.; Mecarozzi, M.; Di Mario, G.; et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. *Cancer Res.* **2009**, *69*, 1314–1323. [[CrossRef](#)]
119. Westhoff, B.; Colaluca, I.N.; D'Ario, G.; Donzelli, M.; Tosoni, D.; Volorio, S.; Pelosi, G.; Spaggiari, L.; Mazzarol, G.; Viale, G. Alterations of the Notch pathway in lung cancer. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 22293–22298. [[CrossRef](#)]
120. Northcott, P.A.; Buchhalter, I.; Morrissy, A.S.; Hovestadt, V.; Weischenfeldt, J.; Ehrenberger, T.; Gröbner, S.; Segura-Wang, M.; Zichner, T.; Rudneva, V.A. the whole-genome landscape of medulloblastoma subtypes. *Nature* **2017**, *547*, 311–317. [[CrossRef](#)]
121. Golan, T.; Messer, A.R.; Amitai-Lange, A.; Melamed, Z.e.; Ohana, R.; Bell, R.E.; Kapitansky, O.; Lerman, G.; Greenberger, S.; Khaled, M. Interactions of melanoma cells with distal keratinocytes trigger metastasis via notch signaling inhibition of MITF. *Mol. Cell* **2015**, *59*, 664–676. [[CrossRef](#)]
122. Zhang, Y.; Li, B.; Ji, Z.Z.; Zheng, P.S. Notch1 regulates the growth of human colon cancers. *Cancer* **2010**, *116*, 5207–5218. [[CrossRef](#)]
123. Reedijk, M.; Odorcic, S.; Zhang, H.; Chetty, R.; Tennert, C.; Dickson, B.C.; Lockwood, G.; Gallinger, S.; Egan, S.E. Activation of Notch signaling in human colon adenocarcinoma. *Int. J. Oncol.* **2008**, *33*, 1223–1229. [[PubMed](#)]
124. Ranganathan, P.; Weaver, K.L.; Capobianco, A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. *Nat. Rev. Cancer* **2011**, *11*, 338–351. [[CrossRef](#)] [[PubMed](#)]
125. Robinson, D.R.; Kalyana-Sundaram, S.; Wu, Y.-M.; Shankar, S.; Cao, X.; Ateeq, B.; Asangani, I.A.; Iyer, M.; Maher, C.A.; Grasso, C.S. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. *Nat. Med.* **2011**, *17*, 1646. [[CrossRef](#)]
126. Gallahan, D.; Callahan, R. the mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). *Oncogene* **1997**, *14*, 1883–1890. [[CrossRef](#)]
127. Harrison, H.; Farnie, G.; Howell, S.J.; Rock, R.E.; Stylianou, S.; Brennan, K.R.; Bundred, N.J.; Clarke, R.B. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. *Cancer Res.* **2010**, *70*, 709–718. [[CrossRef](#)] [[PubMed](#)]
128. Reedijk, M.; Odorcic, S.; Chang, L.; Zhang, H.; Miller, N.; McCready, D.R.; Lockwood, G.; Egan, S.E. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. *Cancer Res.* **2005**, *65*, 8530–8537. [[CrossRef](#)]
129. Ayyanan, A.; Civenni, G.; Ciarloni, L.; Morel, C.; Mueller, N.; Lefort, K.; Mandinova, A.; Raffoul, W.; Fiche, M.; Dotto, G.P. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 3799–3804. [[CrossRef](#)]
130. Weijzen, S.; Rizzo, P.; Braid, M.; Vaishnav, R.; Jonkheer, S.M.; Zlobin, A.; Osborne, B.A.; Gottipati, S.; Aster, J.C.; Hahn, W.C. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. *Nat. Med.* **2002**, *8*, 979–986. [[CrossRef](#)]
131. Fitzgerald, K.; Harrington, A.; Leder, P. Ras pathway signals are required for notch-mediated oncogenesis. *Oncogene* **2000**, *19*, 4191–4198. [[CrossRef](#)]
132. Pickering, C.R.; Zhou, J.H.; Lee, J.J.; Drummond, J.A.; Peng, S.A.; Saade, R.E.; Tsai, K.Y.; Curry, J.L.; Tetzlaff, M.T.; Lai, S.Y.; et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. *Clin. Cancer Res.* **2014**, *20*, 6582–6592. [[CrossRef](#)]
133. South, A.P.; Purdie, K.J.; Watt, S.A.; Haldenby, S.; Den Breems, N.Y.; Dimon, M.; Arron, S.T.; Kluk, M.J.; Aster, J.C.; McHugh, A. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. *J. Investig. Dermatol.* **2014**, *134*, 2630–2638. [[CrossRef](#)] [[PubMed](#)]
134. Agrawal, N.; Frederick, M.J.; Pickering, C.R.; Bettegowda, C.; Chang, K.; Li, R.J.; Fakhry, C.; Xie, T.-X.; Zhang, J.; Wang, J. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science* **2011**, *333*, 1154–1157. [[CrossRef](#)] [[PubMed](#)]
135. Stransky, N.; Egloff, A.M.; Tward, A.D.; Kostic, A.D.; Cibulskis, K.; Sivachenko, A.; Kryukov, G.V.; Lawrence, M.S.; Sougnez, C.; McKenna, A.; et al. the mutational landscape of head and neck squamous cell carcinoma. *Science* **2011**, *333*, 1157–1160. [[CrossRef](#)] [[PubMed](#)]
136. Song, Y.; Li, L.; Ou, Y.; Gao, Z.; Li, E.; Li, X.; Zhang, W.; Wang, J.; Xu, L.; Zhou, Y. Identification of genomic alterations in oesophageal squamous cell cancer. *Nature* **2014**, *509*, 91–95. [[CrossRef](#)] [[PubMed](#)]

137. Rampias, T.; Vgenopoulou, P.; Avgeris, M.; Polyzos, A.; Stravodimos, K.; Valavanis, C.; Scorilas, A.; Klinakis, A. a new tumor suppressor role for the Notch pathway in bladder cancer. *Nat. Med.* **2014**, *20*, 1199–1205. [[CrossRef](#)]
138. Nowell, C.S.; Radtke, F. Notch as a tumour suppressor. *Nat. Rev. Cancer* **2017**, *17*, 145. [[CrossRef](#)]
139. Wang, N.J.; Sanborn, Z.; Arnett, K.L.; Bayston, L.J.; Liao, W.; Proby, C.M.; Leigh, I.M.; Collisson, E.A.; Gordon, P.B.; Jakkula, L.; et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 17761–17766. [[CrossRef](#)]
140. Nicolas, M.; Wolfer, A.; Raj, K.; Kummer, J.A.; Mill, P.; van Noort, M.; Hui, C.-C.; Clevers, H.; Dotto, G.P.; Radtke, F. Notch1 functions as a tumor suppressor in mouse skin. *Nat. Genet.* **2003**, *33*, 416. [[CrossRef](#)]
141. Nguyen, B.-C.; Lefort, K.; Mandinova, A.; Antonini, D.; Devgan, V.; Della Gatta, G.; Koster, M.I.; Zhang, Z.; Wang, J.; Di Vignano, A.T. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. *Genes Dev.* **2006**, *20*, 1028–1042. [[CrossRef](#)]
142. Rangarajan, A.; Talora, C.; Okuyama, R.; Nicolas, M.; Mammucari, C.; Oh, H.; Aster, J.C.; Krishna, S.; Metzger, D.; Chambon, P.; et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. *EMBO J.* **2001**, *20*, 3427–3436. [[CrossRef](#)]
143. Exrance, A. *Alzheimer's Failure Raises Questions about Disease-Modifying Strategies*; Nature Publishing Group: Berlin, Germany, 2010.
144. Doody, R.S.; Raman, R.; Sperling, R.A.; Seimers, E.; Sethuraman, G.; Mohs, R.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Sun, X. Peripheral and central effects of γ -secretase inhibition by semagacestat in Alzheimer's disease. *Alzheimer's Res. Ther.* **2015**, *7*, 36. [[CrossRef](#)] [[PubMed](#)]
145. Henley, D.B.; Sundell, K.L.; Sethuraman, G.; Dowsett, S.A.; May, P.C. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. *Curr. Med. Res. Opin.* **2014**, *30*, 2021–2032. [[CrossRef](#)] [[PubMed](#)]
146. Restivo, G.; Nguyen, B.C.; Dziunycz, P.; Ristorcelli, E.; Ryan, R.J.; Özuysal, Ö.Y.; Di Piazza, M.; Radtke, F.; Dixon, M.J.; Hofbauer, G.F. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. *EMBO J.* **2011**, *30*, 4571–4585. [[CrossRef](#)] [[PubMed](#)]
147. Nowell, C.S.; Odermatt, P.D.; Azzolin, L.; Hohnel, S.; Wagner, E.F.; Fantner, G.E.; Lutolf, M.P.; Barrandon, Y.; Piccolo, S.; Radtke, F. Chronic inflammation imposes aberrant cell fate in regenerating epithelia through mechanotransduction. *Nat. Cell Biol.* **2016**, *18*, 168–180. [[CrossRef](#)] [[PubMed](#)]
148. Demehri, S.; Liu, Z.; Lee, J.; Lin, M.-H.; Crosby, S.D.; Roberts, C.J.; Grigsby, P.W.; Miner, J.H.; Farr, A.G.; Kopan, R. Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. *PLoS Biol.* **2008**, *6*, e123. [[CrossRef](#)]
149. Di Piazza, M.; Nowell, C.S.; Koch, U.; Durham, A.-D.; Radtke, F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. *Cancer Cell* **2012**, *22*, 479–493. [[CrossRef](#)]
150. Viatour, P.; Ehmer, U.; Saddic, L.A.; Dorrell, C.; Andersen, J.B.; Lin, C.; Zmoos, A.-F.; Mazur, P.K.; Schaffer, B.E.; Ostermeier, A. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. *J. Exp. Med.* **2011**, *208*, 1963–1976. [[CrossRef](#)]
151. Giachino, C.; Boulay, J.-L.; Ivanek, R.; Alvarado, A.; Tostado, C.; Lugert, S.; Tchorz, J.; Coban, M.; Mariani, L.; Bettler, B. a tumor suppressor function for notch signaling in forebrain tumor subtypes. *Cancer Cell* **2015**, *28*, 730–742. [[CrossRef](#)]
152. Lee, J.-S.; Chu, I.-S.; Mikaelyan, A.; Calvisi, D.F.; Heo, J.; Reddy, J.K.; Thorgeirsson, S.S. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. *Nat. Genet.* **2004**, *36*, 1306–1311. [[CrossRef](#)]
153. Kawaguchi, K.; Honda, M.; Yamashita, T.; Okada, H.; Shirasaki, T.; Nishikawa, M.; Nio, K.; Arai, K.; Sakai, Y.; Yamashita, T. Jagged1 DNA copy number variation is associated with poor outcome in liver cancer. *Am. J. Pathol.* **2016**, *186*, 2055–2067. [[CrossRef](#)]
154. Ma, L.; Dong, P.; Liu, L.; Gao, Q.; Duan, M.; Zhang, S.; Chen, S.; Xue, R.; Wang, X. Overexpression of protein O-fucosyltransferase 1 accelerates hepatocellular carcinoma progression via the Notch signaling pathway. *Biochem. Biophys. Res. Commun.* **2016**, *473*, 503–510. [[CrossRef](#)] [[PubMed](#)]
155. Koch, U.; Lehal, R.; Radtke, F. Stem cells living with a Notch. *Development* **2013**, *140*, 689–704. [[CrossRef](#)] [[PubMed](#)]

156. Giachino, C.; Basak, O.; Lugert, S.; Knuckles, P.; Obernier, K.; Fiorelli, R.; Frank, S.; Raineteau, O.; Alvarez-Buylla, A.; Taylor, V. Molecular diversity subdivides the adult forebrain neural stem cell population. *Stem Cells* **2014**, *32*, 70–84. [[CrossRef](#)] [[PubMed](#)]
157. Suzuki, H.; Aoki, K.; Chiba, K.; Sato, Y.; Shiozawa, Y.; Shiraishi, Y.; Shimamura, T.; Niida, A.; Motomura, K.; Ohka, F. Mutational landscape and clonal architecture in grade II and III gliomas. *Nat. Genet.* **2015**, *47*, 458. [[CrossRef](#)]
158. Network, C.G.A.R. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. *New Engl. J. Med.* **2015**, *372*, 2481–2498.
159. Klinakis, A.; Lobry, C.; Abdel-Wahab, O.; Oh, P.; Haeno, H.; Buonamici, S.; van De Walle, I.; Cathelin, S.; Trimarchi, T.; Araldi, E.; et al. a novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. *Nature* **2011**, *473*, 230–233. [[CrossRef](#)]
160. Lobry, C.; Ntziachristos, P.; Ndiaye-Lobry, D.; Oh, P.; Cimmino, L.; Zhu, N.; Araldi, E.; Hu, W.; Freund, J.; Abdel-Wahab, O. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. *J. Exp. Med.* **2013**, *210*, 301–319. [[CrossRef](#)]
161. Kannan, S.; Sutphin, R.M.; Hall, M.G.; Golfman, L.S.; Fang, W.; Nolo, R.M.; Akers, L.J.; Hammitt, R.A.; McMurray, J.S.; Kornblau, S.M. Notch activation inhibits AML growth and survival: a potential therapeutic approach. *J. Exp. Med.* **2013**, *210*, 321–337. [[CrossRef](#)]
162. Kode, A.; Manavalan, J.S.; Mosialou, I.; Bhagat, G.; Rathinam, C.V.; Luo, N.; Khiabani, H.; Lee, A.; Murty, V.V.; Friedman, R. Leukaemogenesis induced by an activating β -catenin mutation in osteoblasts. *Nature* **2014**, *506*, 240–244. [[CrossRef](#)]
163. Sorrentino, C.; Cuneo, A.; Roti, G. Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies. *Mediterr. J. Hematol. Infect.* **2019**, *11*, e2019037. [[CrossRef](#)]
164. Nickoloff, B.J.; Osborne, B.A.; Miele, L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. *Oncogene* **2003**, *22*, 6598–6608. [[CrossRef](#)] [[PubMed](#)]
165. Rizzo, P.; Osipo, C.; Foreman, K.; Golde, T.; Osborne, B.; Miele, L. Rational targeting of Notch signaling in cancer. *Oncogene* **2008**, *27*, 5124–5131. [[CrossRef](#)] [[PubMed](#)]
166. Hounjet, J.; Habets, R.; Schaaf, M.B.; Hendrickx, T.C.; Barbeau, L.M.O.; Yahyanejad, S.; Rouschop, K.M.; Groot, A.J.; Vooijs, M. the anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to γ -secretase inhibition. *Oncogene* **2019**, *38*, 5457–5468. [[CrossRef](#)] [[PubMed](#)]
167. Pinazza, M.; Ghisi, M.; Minuzzo, S.; Agnusdei, V.; Fossati, G.; Ciminale, V.; Pezzè, L.; Ciribilli, Y.; Pilotto, G.; Venturoli, C.; et al. Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. *Oncogene* **2018**, *37*, 3839–3851. [[CrossRef](#)] [[PubMed](#)]
168. Schneider, M.; Troost, T.; Grawe, F.; Martinez-Arias, A.; Klein, T. Activation of Notch in IgD mutant cells requires the fusion of late endosomes with the lysosome. *J. Cell Sci.* **2013**, *126*, 645–656. [[CrossRef](#)] [[PubMed](#)]
169. Habets, R.A.; de Bock, C.E.; Serneels, L.; Lodewijckx, I.; Verbeke, D.; Nittner, D.; Narlawar, R.; Demeyer, S.; Dooley, J.; Liston, A.; et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. *Sci. Transl. Med.* **2019**, *11*, eaau6246. [[CrossRef](#)]
170. Roti, G.; Carlton, A.; Ross, K.N.; Markstein, M.; Pajcini, K.; Su, A.H.; Perrimon, N.; Pear, W.S.; Kung, A.L.; Blacklow, S.C.; et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. *Cancer Cell* **2013**, *23*, 390–405. [[CrossRef](#)]
171. Nolin, E.; Gans, S.; Llamas, L.; Bandyopadhyay, S.; Brittain, S.M.; Bernasconi-Elias, P.; Carter, K.P.; Loureiro, J.J.; Thomas, J.R.; Schirle, M.; et al. Discovery of a ZIP7 inhibitor from a Notch pathway screen. *Nat. Chem. Biol.* **2019**, *15*, 179–188. [[CrossRef](#)]
172. Periz, G.; Fortini, M.E. Ca(2+)-ATPase function is required for intracellular trafficking of the Notch receptor in *Drosophila*. *EMBO J.* **1999**, *18*, 5983–5993. [[CrossRef](#)]
173. Doan, N.T.; Paulsen, E.S.; Sehgal, P.; Moller, J.V.; Nissen, P.; Denmeade, S.R.; Isaacs, J.T.; Dionne, C.A.; Christensen, S.B. Targeting thapsigargin towards tumors. *Steroids* **2015**, *97*, 2–7. [[CrossRef](#)]
174. Sagara, Y.; Wade, J.; Inesi, G. a conformational mechanism for formation of a dead-end complex by the sarcoplasmic reticulum ATPase with thapsigargin. *J. Biol. Chem.* **1992**, *267*, 1286–1292. [[PubMed](#)]
175. Toyoshima, C.; Nomura, H. Structural changes in the calcium pump accompanying the dissociation of calcium. *Nature* **2002**, *418*, 605–611. [[CrossRef](#)] [[PubMed](#)]

176. Wong, G.T.; Manfra, D.; Poulet, F.M.; Zhang, Q.; Josien, H.; Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J.S.; Lee, H.J.; et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. *J. Biol. Chem.* **2004**, *279*, 12876–12882. [[CrossRef](#)] [[PubMed](#)]
177. Lytton, J.; Westlin, M.; Hanley, M.R. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. *J. Biol. Chem.* **1991**, *266*, 17067–17071. [[PubMed](#)]
178. Denmeade, S.R.; Jakobsen, C.M.; Janssen, S.; Khan, S.R.; Garrett, E.S.; Lilja, H.; Christensen, S.B.; Isaacs, J.T. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. *J. Nat. Cancer Inst.* **2003**, *95*, 990–1000. [[CrossRef](#)]
179. Mahalingam, D.; Peguero, J.; Cen, P.; Arora, S.P.; Sarantopoulos, J.; Rowe, J.; Allgood, V.; Tubb, B.; Campos, L. a Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. *Cancers* **2019**, *11*, 833. [[CrossRef](#)] [[PubMed](#)]
180. Denmeade, S.R.; Mhaka, A.M.; Rosen, D.M.; Brennen, W.N.; Dalrymple, S.; Dach, I.; Olesen, C.; Gurel, B.; Demarzo, A.M.; Wilding, G.; et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. *Sci. Transl. Med.* **2012**, *4*, 140ra186. [[CrossRef](#)]
181. Roti, G.; Qi, J.; Kitara, S.; Sanchez-Martin, M.; Saur Conway, A.; Varca, A.C.; Su, A.; Wu, L.; Kung, A.L.; Ferrando, A.A.; et al. Leukemia-specific delivery of mutant NOTCH1 targeted therapy. *J. Exp. Med.* **2018**, *215*, 197–216. [[CrossRef](#)]
182. Liu, Z.-C.; Yang, Z.-X.; Zhou, J.-S.; Zhang, H.-T.; Huang, Q.-K.; Dang, L.-L.; Liu, G.-X.; Tao, K.-S. Curcumin regulates hepatoma cell proliferation and apoptosis through the Notch signaling pathway. *Int. J. Clin. Exp. Med.* **2014**, *7*, 714.
183. Subramaniam, D.; Ponnurangam, S.; Ramamoorthy, P.; Standing, D.; Battafarano, R.J.; Anant, S.; Sharma, P. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. *PLoS ONE* **2012**, *7*, e30590. [[CrossRef](#)]
184. Li, Y.; Zhang, J.; Ma, D.; Zhang, L.; Si, M.; Yin, H.; Li, J. Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling. *FEBS J.* **2012**, *279*, 2247–2259. [[CrossRef](#)] [[PubMed](#)]
185. Aridoss, G.; Zhou, B.; Hermanson, D.L.; Bleeker, N.P.; Xing, C. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment. *J. Med. Chem.* **2012**, *55*, 5566–5581. [[CrossRef](#)] [[PubMed](#)]
186. Bleeker, N.P.; Cornea, R.L.; Thomas, D.D.; Xing, C. a novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML. *Mol. Pharm.* **2013**, *10*, 4358–4366. [[CrossRef](#)] [[PubMed](#)]
187. De Ford, C.; Calderón, C.; Sehgal, P.; Fedosova, N.U.; Murillo, R.; Olesen, C.; Nissen, P.; Møller, J.V.; Merfort, I. Discovery of Tricyclic Clerodane Diterpenes as Sarco/Endoplasmic Reticulum Ca²⁺-ATPase Inhibitors and Structure–Activity Relationships. *J. Nat. Prod.* **2015**, *78*, 1262–1270. [[CrossRef](#)] [[PubMed](#)]
188. De Ford, C.; Heidersdorf, B.; Haun, F.; Murillo, R.; Friedrich, T.; Borner, C.; Merfort, I. the clerodane diterpene casearin J induces apoptosis of T-ALL cells through SERCA inhibition, oxidative stress, and interference with Notch1 signaling. *Cell Death Dis.* **2016**, *7*, e2070. [[CrossRef](#)] [[PubMed](#)]
189. Marchesini, M.; Gherli, A.; Montanaro, A.; Patrizi, L.; Sorrentino, C.; Pagliaro, L.; Rompietti, C.; Kitara, S.; Heit, S.; Olesen, C.E.; et al. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. *Cell Chem. Biol.* **2020**, *27*, 678–697. [[CrossRef](#)]
190. Sehgal, P.; Szalai, P.; Olesen, C.; Praetorius, H.A.; Nissen, P.; Christensen, S.B.; Engedal, N.; Møller, J.V. Inhibition of the sarco/endoplasmic reticulum (ER) Ca²⁺-ATPase by thapsigargin analogs induces cell death via ER Ca²⁺ depletion and the unfolded protein response. *J. Biol. Chem.* **2017**, *292*, 19656–19673. [[CrossRef](#)]
191. Hollingshead, L.M.; Faulds, D.; Fitton, A. Bepridil. a review of its pharmacological properties and therapeutic use in stable angina pectoris. *Drugs* **1992**, *44*, 835–857. [[CrossRef](#)]
192. Roti, G.; Ross, K.; Ferrando, A.; Blacklow, S.; Aster, J.; Stegmaier, K. Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL. *Blood* **2009**, *114*, 366. [[CrossRef](#)]

193. Arruga, F.; Gizdic, B.; Serra, S.; Vaisitti, T.; Ciardullo, C.; Coscia, M.; Laurenti, L.; D’Arena, G.; Jaksic, O.; Inghirami, G. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. *Leukemia* **2014**, *28*, 1060. [[CrossRef](#)]
194. Groth, C.; Sasamura, T.; Khanna, M.R.; Whitley, M.; Fortini, M.E. Protein trafficking abnormalities in Drosophila tissues with impaired activity of the ZIP7 zinc transporter Catsup. *Development* **2013**, *140*, 3018–3027. [[CrossRef](#)] [[PubMed](#)]
195. Fischer, I.; Gagner, J.P.; Law, M.; Newcomb, E.W.; Zagzag, D. Angiogenesis in gliomas: Biology and molecular pathophysiology. *Brain Pathol.* **2005**, *15*, 297–310. [[CrossRef](#)] [[PubMed](#)]
196. Zhang, X.; Chen, T.; Zhang, J.; Mao, Q.; Li, S.; Xiong, W.; Qiu, Y.; Xie, Q.; Ge, J. Notch1 promotes glioma cell migration and invasion by stimulating β -catenin and NF- κ B signaling via AKT activation. *Cancer Sci.* **2012**, *103*, 181–190. [[CrossRef](#)] [[PubMed](#)]
197. Rao, J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. *Nat. Rev. Cancer* **2003**, *3*, 489–501. [[CrossRef](#)] [[PubMed](#)]
198. Sidenius, N.; Blasi, F. the urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. *Cancer Metastasis Rev.* **2003**, *22*, 205–222. [[CrossRef](#)]
199. Raghu, H.; Gondi, C.S.; Dinh, D.H.; Gujrati, M.; Rao, J.S. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor. *Mol. Cancer* **2011**, *10*, 130. [[CrossRef](#)]
200. Kanwar, R.; Fortini, M.E. Notch signaling: a different sort makes the cut. *Curr. Biol.* **2004**, *14*, R1043–R1045. [[CrossRef](#)]
201. Weber, U.; Eroglu, C.; Mlodzik, M. Phospholipid membrane composition affects EGF receptor and Notch signaling through effects on endocytosis during Drosophila development. *Dev. Cell* **2003**, *5*, 559–570. [[CrossRef](#)]
202. Sakamoto, K.; Aldana-Masangkay, G. the role of HDAC6 in cancer. *J. Biomed. Biotechnol.* **2011**, *2011*, 10.
203. Gao, Y.-s.; Hubbert, C.C.; Yao, T.-P. the microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. *J. Biol. Chem.* **2010**, *285*, 11219–11226. [[CrossRef](#)]
204. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. *Nat. Rev. Drug Dis.* **2006**, *5*, 769–784. [[CrossRef](#)] [[PubMed](#)]
205. Mosquera, J.M.; Sboner, A.; Zhang, L.; Chen, C.L.; Sung, Y.S.; Chen, H.W.; Agaram, N.P.; Briskin, D.; Basha, B.M.; Singer, S. Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. *Genes Chromosomes Cancer* **2013**, *52*, 1075–1087. [[CrossRef](#)] [[PubMed](#)]
206. Tzoneva, G.; Ferrando, A.A. Recent advances on NOTCH signaling in T-ALL. *Curr. Top. Microbiol. Immunol.* **2012**, *360*, 163–182. [[CrossRef](#)] [[PubMed](#)]
207. Kaether, C.; Haass, C.; Steiner, H. Assembly, trafficking and function of γ -secretase. *Neurodegener. Dis.* **2006**, *3*, 275–283. [[CrossRef](#)] [[PubMed](#)]
208. Green, K.N.; Demuro, A.; Akbari, Y.; Hitt, B.D.; Smith, I.F.; Parker, I.; LaFerla, F.M. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. *J. Cell. Biol.* **2008**, *181*, 1107–1116. [[CrossRef](#)]
209. Liu, Y.; Easton, J.; Shao, Y.; Maciaszek, J.; Wang, Z.; Wilkinson, M.R.; McCastlain, K.; Edmonson, M.; Pounds, S.B.; Shi, L. the genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nat. Genet.* **2017**, *49*, 1211. [[CrossRef](#)]
210. Atak, Z.K.; Gianfelici, V.; Hulselmans, G.; De Keersmaecker, K.; Devasia, A.G.; Geerdens, E.; Mentens, N.; Chiaretti, S.; Durinck, K.; Uyttebroeck, A. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. *PLoS Genet.* **2013**, *9*, e1003997. [[CrossRef](#)]
211. Milano, J.; McKay, J.; Dagenais, C.; Foster-Brown, L.; Pognan, F.; Gadiant, R.; Jacobs, R.T.; Zacco, A.; Greenberg, B.; Ciaccio, P.J. Modulation of notch processing by γ -secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. *Toxicol. Sci.* **2004**, *82*, 341–358. [[CrossRef](#)]

212. Deangelo, D.J.; Stone, R.M.; Silverman, L.B.; Stock, W.; Attar, E.C.; Fearen, I.; Dallob, A.; Matthews, C.; Stone, J.; Freedman, S.J.; et al. a phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. *J. Clin. Oncol.* **2006**, *24*, 6585. [[CrossRef](#)]
213. Mukherjee, N.; Almeida, A.; Partyka, K.A.; Lu, Y.; Schwan, J.V.; Lambert, K.; Rogers, M.; Robinson, W.A.; Robinson, S.E.; Applegate, A.J. Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. *Oncotarget* **2016**, *7*, 84594. [[CrossRef](#)]
214. Real, P.J.; Ferrando, A.A. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. *Leukemia* **2009**, *23*, 1374–1377. [[PubMed](#)]
215. Shi, T.-T.; Yu, X.-X.; Yan, L.-J.; Xiao, H.-T. Research progress of hydroxychloroquine and autophagy inhibitors on cancer. *Cancer Chemother. Pharmacol.* **2017**, *79*, 287–294. [[PubMed](#)]
216. De Strooper, B.; Vassar, R.; Golde, T. the secretases: Enzymes with therapeutic potential in Alzheimer disease. *Nat. Rev. Neurol* **2010**, *6*, 99–107. [[CrossRef](#)] [[PubMed](#)]
217. Cullion, K.; Draheim, K.M.; Hermance, N.; Tammam, J.; Sharma, V.M.; Ware, C.; Nikov, G.; Krishnamoorthy, V.; Majumder, P.K.; Kelliher, M.A. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. *Blood* **2009**, *113*, 6172–6181. [[CrossRef](#)] [[PubMed](#)]
218. Papayannidis, C.; DeAngelo, D.J.; Stock, W.; Huang, B.; Shaik, M.N.; Cesari, R.; Zheng, X.; Reynolds, J.M.; English, P.A.; Ozeck, M.; et al. a Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. *Blood Cancer J.* **2015**, *5*, e350. [[CrossRef](#)]
219. Zweidler-McKay, P.A.; DeAngelo, D.J.; Douer, D.; Dombret, H.; Ottmann, O.G.; Vey, N.; Thomas, D.A.; Zhu, L.; Huang, F.; Bajaj, G. the safety and activity of BMS-906024, a gamma secretase inhibitor (GSI) with anti-notch activity. In *Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial*; American Society of Hematology: Washington, DC, USA, 2014.
220. Knoechel, B.; Bhatt, A.; Pan, L.; Pedomallu, C.S.; Severson, E.; Gutierrez, A.; Dorfman, D.M.; Kuo, F.C.; Kluk, M.; Kung, A.L.; et al. Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ -secretase inhibitor BMS-906024: Genetic and epigenetic findings in an outlier case. *Cold Spring Harb. Mol. Case Stud.* **2015**, *1*, a000539. [[CrossRef](#)]
221. Riccio, O.; van Gijn, M.E.; Bezdek, A.C.; Pellegrinet, L.; van Es, J.H.; Zimmer-Strobl, U.; Strobl, L.J.; Honjo, T.; Clevers, H.; Radtke, F. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. *EMBO Rep.* **2008**, *9*, 377–383. [[CrossRef](#)]
222. Filipović, A.; Lombardo, Y.; Faronato, M.; Abrahams, J.; Aboagye, E.; Nguyen, Q.D.; d'Aqua, B.B.; Ridley, A.; Green, A.; Rahka, E.; et al. Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. *Breast Cancer Res. Treat.* **2014**, *148*, 455–462. [[CrossRef](#)]
223. Arai, M.A.; Akamine, R.; Tsuchiya, A.; Yoneyama, T.; Koyano, T.; Kowithayakorn, T.; Ishibashi, M. the Notch inhibitor cowanin accelerates nicastrin degradation. *Sci. Rep.* **2018**, *8*, 5376. [[CrossRef](#)]
224. Suisse, A.; Treisman, J.E. Reduced SERCA Function Preferentially Affects Wnt Signaling by Retaining E-Cadherin in the Endoplasmic Reticulum. *Cell Rep.* **2019**, *26*, 322–329. [[CrossRef](#)]
225. Wu, R.; Yang, H.; Wan, J.; Deng, X.; Chen, L.; Hao, S.; Ma, L. Knockdown of the Hippo transducer YAP reduces proliferation and promotes apoptosis in the Jurkat leukemia cell. *Mol. Med. Rep.* **2018**, *18*, 5379–5388. [[CrossRef](#)] [[PubMed](#)]

